[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 8844
1. Neipp M, Schwarz A, Pertschy S, Klempnauer J, Becker T: Accidental transplantation of a kidney with a cystic renal cell carcinoma following living donation: management and 1 yr follow-up. Clin Transplant; 2006 Mar-Apr;20(2):147-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accidental transplantation of a kidney with a cystic renal cell carcinoma following living donation: management and 1 yr follow-up.
  • Transmission of cancer is a fatal risk in organ transplantation.
  • We present a case of incidental renal carcinoma in a kidney obtained from a living donor.
  • An MRT scan revealed two cysts in the right kidney.
  • Right-sided donor nephrectomy and subsequent transplantation was performed.
  • Histology revealed a high-grade renal clear cell carcinoma 10 d after transplantation.
  • Donor and recipient are without evidence of tumor recurrence 1 yr after transplantation.
  • Our policy to obtain the kidney presenting anatomical variations proved to be beneficial for the donor.
  • In case of transmission of cancer partial resection preserving graft function might be justified.
  • [MeSH-major] Carcinoma, Renal Cell. Kidney Failure, Chronic / surgery. Kidney Neoplasms. Kidney Transplantation / methods. Living Donors. Medical Errors
  • [MeSH-minor] Adult. Female. Humans. Kidney Diseases, Cystic / surgery. Male. Middle Aged. Nephrectomy. Peritoneal Dialysis. Treatment Outcome


2. Rao Q, Zhou XJ, Wu B, Ma HH, Zhou HB, Liu XH, Chen JY: [Renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: a study of 11 cases and review of literature]. Zhonghua Bing Li Xue Za Zhi; 2007 Apr;36(4):244-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: a study of 11 cases and review of literature].
  • OBJECTIVE: To study the clinicopathologic features, differential diagnosis and prognosis of renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.
  • METHODS: The histopathologic findings and immunophenotype of 11 cases of renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions were studied.
  • The diameter of the tumors varied from 2.5 to 6.0 cm.
  • Histologically, two morphologic patterns were seen.
  • The first pattern consisted of alveolar, papillary or nested architecture.
  • The tumor cells contained voluminous, clear to eosinophilic cytoplasm, distinct cell borders, vesicular chromatin, and prominent nucleoli.
  • The tumor cells possessed less abundant cytoplasm and inconspicuous nucleoli.
  • CONCLUSIONS: Renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions is a newly described but rarely encountered subtype of renal cell carcinoma.
  • Pathologic diagnosis can be established when taken age of the patients, histopathologic findings and immunoreactivity for TFE3 protein into consideration.
  • [MeSH-major] Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / metabolism. Carcinoma, Renal Cell / genetics. Chromosomes, Human, X. Kidney Neoplasms / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706115.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / TFE3 protein, human; EC 3.4.24.11 / Neprilysin; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


3. Santos Arrontes D, Fernández Aceñero MJ, García González JI, Martín Muñoz M, Paniagua Andrés P: Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index. J Urol; 2008 Mar;179(3):857-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index.
  • PURPOSE: We assessed the convenience of elective surgery for clear cell renal carcinoma with regard to overall survival in accordance with established comorbidity criteria.
  • MATERIAL AND METHODS: This retrospective study included all patients with a histological diagnosis of clear cell renal carcinoma diagnosed between July 1, 1983 and June 1, 2006 in a population of 200,000 inhabitants.
  • All tumors were classified in stages according to the classification of the American Joint Committee on Cancer based on the 2002 UICC TNM classification.
  • Study variables were gender, age, smoking, Charlson index, Charlson index 2 or less and greater than 2, tumor stage, localized stage and locally advanced or metastatic stage.
  • Survival associated with each tumor stage and comorbidity group was evaluated by the Kaplan-Meier test.
  • RESULTS: A total of 232 renal masses were diagnosed during the study period, of which 192 (82.7%) were useful for the study.
  • There were no significant differences between the genders in age (p = 0.486), stage (p = 0.659) and Charlson index (p = 0.463).
  • Stage was I to IV in 29 (15.1%), 69 (35.9%), 40 (20.8%) and 47 cases (24.5%), respectively.
  • It proved impossible to determine tumor stage in 4 cases (2.1%).
  • There were 72 deaths (37.5%), including 25 (34.7%) from intercurrent disease and 45 (62.5%) from clear cell renal carcinoma.
  • Survival analysis revealed significant differences in overall survival according to stage (p <0.001) and Charlson index (p = 0.02), between localized stages and locally advanced or metastatic stages (p <0.001) and between patients with a Charlson index of 2 or less vs greater than 2 (p <0.001), particularly in those with local stage (p <0.001) but not in those with locally advanced or metastatic stage (p >0.05).
  • In the logistical regression model tumor stage and the comorbidity index were prognostic factors after 1 year (B exponential 2.4 and 1.3, respectively, p <0.05), after 5 years (B exponential 1.6 and 1.3, p <0.05) and after 10 years (B exponential 1.5 and 1.4, respectively, p <0.05).
  • CONCLUSIONS: Patients with localized clear cell renal carcinoma and a comorbidity index of greater than 2 may choose observation as treatment for the condition.
  • [MeSH-major] Carcinoma, Renal Cell / epidemiology. Kidney Neoplasms / epidemiology


Advertisement
4. Gallucci M, Guaglianone S, Carpanese L, Papalia R, Simone G, Forestiere E, Leonardo C: Superselective embolization as first step of laparoscopic partial nephrectomy. Urology; 2007 Apr;69(4):642-5; discussion 645-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Laparoscopic partial nephrectomy is currently very hard to perform because of the great difficulty in obtaining renal parenchymal hemostasis during tumor excision and the consequent high risk of bleeding.
  • The aim of this study was to propose a method to decrease the risk of bleeding, consisting of the superselective embolization of tumor vessels before performing the laparoscopic partial nephrectomy.
  • METHODS: Fifty patients with small, solitary, enhancing, predominantly exophytic renal tumors underwent a superselective radiographically guided embolization of tumor vessels.
  • The final pathologic evaluation confirmed the diagnosis of renal cell carcinoma in 43 cases.
  • The procedure does not require any regional vascular control or clamping, reduces the estimated blood loss, and reduces the operative time.
  • [MeSH-major] Embolization, Therapeutic / methods. Hemostasis, Surgical / methods. Kidney Neoplasms / surgery. Laparoscopy. Nephrectomy / methods

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17445641.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Zucchetto A, Dal Maso L, Tavani A, Montella M, Ramazzotti V, Talamini R, Canzonieri V, Garbeglio A, Negri E, Franceschi S, La Vecchia C: History of treated hypertension and diabetes mellitus and risk of renal cell cancer. Ann Oncol; 2007 Mar;18(3):596-600
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] History of treated hypertension and diabetes mellitus and risk of renal cell cancer.
  • BACKGROUND: An increased risk of renal cell cancer (RCC) has been reported in subjects with hypertension.
  • Whether this association may vary according to sex, smoking, obesity, or RCC clinical presentation is unclear.
  • Results on the link between diabetes mellitus and RCC are inconclusive.
  • PATIENTS AND METHODS: We conducted an Italian multicenter case-control study, including 767 (494 men, 273 women) incident cases of RCC, under 80 years of age, and 1534 hospital controls, frequency-matched to cases.
  • Multiple logistic regression models, conditioned to center, sex, and age, and adjusted for period of interview, education, smoking, and body mass were used to estimate odds ratios (OR).
  • RESULTS: Compared with subjects never treated, patients with a history of treated hypertension [OR = 1.7, 95% confidence interval (CI) 1.4-2.1] reported an excess risk of RCC.
  • This pattern was confirmed in different strata of sex, education, smoking habits, body mass, tumor histological type, stage, or grade.
  • The attributable risk of RCC for treated hypertension in this population was 16%.
  • CONCLUSION: A possible causal role of hypertension in renal cell carcinogenesis is supported by the consistency of the direct association.


6. Krishnamachary B, Zagzag D, Nagasawa H, Rainey K, Okuyama H, Baek JH, Semenza GL: Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res; 2006 Mar 1;66(5):2725-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.
  • A critical event in the pathogenesis of invasive and metastatic cancer is E-cadherin loss of function.
  • Renal clear cell carcinoma (RCC) is characterized by loss of function of the von Hippel-Lindau tumor suppressor (VHL), which negatively regulates hypoxia-inducible factor-1 (HIF-1).
  • Loss of E-cadherin expression and decreased cell-cell adhesion in VHL-null RCC4 cells were corrected by enforced expression of VHL, a dominant-negative HIF-1alpha mutant, or a short hairpin RNA directed against HIF-1alpha.
  • In human RCC biopsies, expression of E-cadherin and HIF-1alpha was mutually exclusive.
  • The expression of mRNAs encoding TCF3, ZFHX1A, and ZFHX1B, which repress E-cadherin gene transcription, was increased in VHL-null RCC4 cells in a HIF-1-dependent manner.
  • Thus, HIF-1 contributes to the epithelial-mesenchymal transition in VHL-null RCC by indirect repression of E-cadherin.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / physiology. Cadherins / biosynthesis. Carcinoma, Renal Cell / metabolism. Homeodomain Proteins / physiology. Hypoxia-Inducible Factor 1 / physiology. Kidney Neoplasms / metabolism. Repressor Proteins / physiology. Transcription Factors / physiology. Von Hippel-Lindau Tumor Suppressor Protein / physiology
  • [MeSH-minor] Biopsy. Cell Adhesion / physiology. Down-Regulation. Epithelial Cells / pathology. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Mesoderm / pathology. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. RNA, Small Interfering / genetics. Transcription, Genetic

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16510593.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50-CA103175
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Cadherins; 0 / Homeodomain Proteins; 0 / Hypoxia-Inducible Factor 1; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Repressor Proteins; 0 / TCF3 protein, human; 0 / Transcription Factors; 0 / ZEB1 protein, human; 0 / ZEB2 protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


7. Dolley-Hitze T, Jouan F, Martin B, Mottier S, Edeline J, Moranne O, Le Pogamp P, Belaud-Rotureau MA, Patard JJ, Rioux-Leclercq N, Vigneau C: Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? Br J Cancer; 2010 Nov 23;103(11):1698-705
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma?
  • BACKGROUND: The growth factor Angiotensin-2 signals through Angiotensin receptor type 1 (AT1-R) in a broad range of cell types and tumours and through the type-2 receptor (AT2-R) in a more restricted group of cell types.
  • Although numerous forms of cancer have been shown to overexpress AT1-R, expression of AT1-R and AT2-R by human renal clear-cell carcinoma (RCCC) is not well understood.
  • METHODS: Angiotensin receptor type 1 and AT2-R expressions were quantified on tumour tissues by immunohistochemistry (IHC), western blot and quantitative reverse transcriptase PCR (qRT-PCR).
  • By IHC, AT1-R and AT2-R were expressed to a greater level in high-grade tumours (AT1-R: P<0.001, AT2-R: P<0.001).
  • By multivariate analysis, only AT2-R expression correlated with PFS (HR 1.021, P=0.006) and cancer stage (P<0.001).
  • [MeSH-major] Carcinoma, Renal Cell / mortality. Kidney Neoplasms / mortality. Receptor, Angiotensin, Type 1 / analysis. Receptor, Angiotensin, Type 2 / analysis
  • [MeSH-minor] Angiotensin Receptor Antagonists / therapeutic use. Blotting, Western. Disease-Free Survival. Humans. Immunohistochemistry. Multivariate Analysis. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Sep 1;275(35):26765-71 [10837481.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 May;66(1):79-87 [19771429.001]
  • [Cites] Circ Res. 2001 Jan 19;88(1):22-9 [11139469.001]
  • [Cites] Trends Endocrinol Metab. 2000 Jan-Feb;11(1):1-6 [10652498.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1633-7 [11337361.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2462-70 [11745304.001]
  • [Cites] Anticancer Drugs. 2002 Mar;13(3):221-8 [11984065.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4176-9 [12154013.001]
  • [Cites] J Cell Physiol. 2003 Aug;196(2):370-7 [12811831.001]
  • [Cites] Mol Cancer Ther. 2003 Nov;2(11):1139-47 [14617787.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):6038-45 [14676130.001]
  • [Cites] Br J Cancer. 2004 Mar 8;90(5):1059-68 [14997208.001]
  • [Cites] Int J Cancer. 2004 Nov 1;112(2):329-34 [15352048.001]
  • [Cites] Am J Surg Pathol. 1982 Oct;6(7):655-63 [7180965.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] J Urol. 1994 Jan;151(1):208-13 [8254815.001]
  • [Cites] J Clin Invest. 1995 Feb;95(2):651-7 [7860748.001]
  • [Cites] Am J Physiol. 1997 Feb;272(2 Pt 2):R662-8 [9124492.001]
  • [Cites] Exp Nephrol. 1997 May-Jun;5(3):253-62 [9208286.001]
  • [Cites] Kidney Int. 1997 Sep;52(3):699-705 [9291190.001]
  • [Cites] Lancet. 1998 Jul 18;352(9123):179-84 [9683206.001]
  • [Cites] Nephron. 1998 Sep;80(1):25-34 [9730699.001]
  • [Cites] J Am Soc Nephrol. 1999 Jan;10 Suppl 11:S149-61 [9892156.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2686-94 [15814650.001]
  • [Cites] J Hepatol. 2005 May;42(5):687-93 [15826718.001]
  • [Cites] Oncol Rep. 2006 Jan;15(1):155-9 [16328049.001]
  • [Cites] J Cell Physiol. 2010 Oct;225(1):168-73 [20458733.001]
  • [Cites] Cancer Biol Ther. 2007 Aug;6(8):1218-26 [18059164.001]
  • [Cites] Med Oncol. 2010 Sep;27(3):899-906 [19757215.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):552-60 [16434990.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):895-903 [16954438.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Apr;22(4):577-84 [17376054.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):996-1005; discussion 1005-6 [17481528.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1206-12 [17548686.001]
  • [Cites] Hum Pathol. 2007 Oct;38(10):1489-95 [17597181.001]
  • [Cites] Hypertension. 2008 Feb;51(2):252-8 [18086946.001]
  • [Cites] Gynecol Oncol. 2008 Jun;109(3):418-25 [18395779.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):160-6 [18594540.001]
  • [Cites] J Mol Histol. 2008 Aug;39(4):351-8 [18438736.001]
  • [Cites] Int J Urol. 2008 Sep;15(9):848-50 [18786206.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5422-8 [18936475.001]
  • [Cites] Chin Med J (Engl). 2008 Nov 5;121(21):2167-71 [19080179.001]
  • [Cites] Biomed Pharmacother. 2009 Feb;63(2):136-45 [18691848.001]
  • [Cites] Urology. 2009 Mar;73(3):655-60 [19167032.001]
  • [Cites] Leuk Res. 2009 Jun;33(6):810-6 [19010543.001]
  • [Cites] Cancer. 2009 May 15;115(10 Suppl):2306-12 [19402073.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10284-9 [19487683.001]
  • [Cites] Oncol Rep. 2009 Aug;22(2):355-60 [19578777.001]
  • [Cites] Prostate. 2009 Sep 1;69(12):1334-42 [19517575.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Oct;135(10):1429-35 [19399518.001]
  • [Cites] Prostate. 2010 Feb 1;70(2):162-9 [19760626.001]
  • [Cites] J Gastrointest Surg. 2009 Dec;13(12):2189-200 [19816747.001]
  • [Cites] Kidney Int. 2000 Dec;58(6):2437-51 [11115077.001]
  • (PMID = 21102591.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiotensin Receptor Antagonists; 0 / Receptor, Angiotensin, Type 1; 0 / Receptor, Angiotensin, Type 2
  • [Other-IDs] NLM/ PMC2994218
  •  go-up   go-down


8. Hallscheidt PJ, Fink C, Haferkamp A, Bock M, Luburic A, Zuna I, Noeldge G, Kauffmann G: Preoperative staging of renal cell carcinoma with inferior vena cava thrombus using multidetector CT and MRI: prospective study with histopathological correlation. J Comput Assist Tomogr; 2005 Jan-Feb;29(1):64-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative staging of renal cell carcinoma with inferior vena cava thrombus using multidetector CT and MRI: prospective study with histopathological correlation.
  • OBJECTIVE: To evaluate the accuracy of multidetector computed tomography (CT) and magnetic resonance imaging (MRI) in staging and estimating renal carcinomas with caval thrombus.
  • The results the tumor thrombus extension and staging results of 2 independent readers were correlated with surgical and histopathological staging.
  • Readers I and II evaluated the uppermost extension of the cranial tumor thrombus by both CT and MRI.
  • CONCLUSION: In cases of a suspected tumor thrombus, MRI and multidetector CT imaging showed similar staging results.
  • Consequently, these staging modalities can be used to assess the extension of the tumor thrombus.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Iohexol / analogs & derivatives. Kidney Neoplasms / diagnosis. Magnetic Resonance Imaging. Neoplastic Cells, Circulating / pathology. Tomography, Spiral Computed. Vena Cava, Inferior / pathology. Venous Thrombosis / diagnosis


9. Nakaigawa N, Yao M, Kondo K, Kishida T, Noguchi K, Kubota Y, Nagashima Y, Kawano N, Inayama Y, Nozawa A: [Chromophobe renal cell carcinoma: a clinicopathological study of 16 cases]. Hinyokika Kiyo; 2006 Jan;52(1):1-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chromophobe renal cell carcinoma: a clinicopathological study of 16 cases].
  • Pathological characteristics, patient outcome, and preoperative examinations of 16 cases (4.1%) of chromophobe renal cell carcinoma (RCC) observed among 389 patients with RCC treated at Yokohama City University Hospital and Yokohama City University Medical Center between 1991 and 2004 were analyzed.
  • Pathologically, 14 patients had pure chromophobe RCC, and two patients had chromophobe RCC coexisting with aggressive pathological elements, that is, sarcomatoid change in one patient and collecting duct carcinoma in the other.
  • The average tumor size was 7.1 +/- 4.1 cm.
  • Fourteen cases showing pure chromophobe RCC did not metastases on preoperative examination.
  • The patient with a mixture of chromophobe RCC and sarcomatoid change (pT3aN0M0) died of multiple lung metastases 18 months after nephrectomy.
  • The patient showing a mixture of chromophobe RCC and collecting duct carcinoma demonstrated metastases to the paraaortic lymph nodes at preoperative examination (pT1bN2M0), and died of multiple lung and bone metastases and carcinomatous peritonitis 8 months after nephrectomy.
  • The patients with pure chromophobe RCC had a favorable prognosis, but those with a mixed type including aggressive elements such as sarcomatoid change or collecting duct carcinoma, showed a poor clinical course.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Nephrectomy


10. Nathan P, Chao D, Brock C, Savage P, Harries M, Gore M, Eisen T: The place of VEGF inhibition in the current management of renal cell carcinoma. Br J Cancer; 2006 May 8;94(9):1217-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The place of VEGF inhibition in the current management of renal cell carcinoma.
  • Vascular endothelial growth factor (VEGF) is overexpressed in around 80% of patients with clear cell carcinoma of the kidney owing to the inactivation of von Hippel Lindau gene activity.
  • A significant body of evidence has accumulated demonstrating that antagonism of VEGF and its downstream pathways is clinically useful in a significant proportion of patients with metastatic clear cell carcinoma of the kidney.
  • Enough data is now available to recommend that patients with metastatic clear cell carcinoma of the kidney should at some point during the course of their disease be offered entry into a clinical trial enabling exposure to a targeted inhibitor of VEGF or its signalling pathways.
  • [MeSH-major] Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Vascular Endothelial Growth Factor A / physiology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2005 Oct;16(10):1688-94 [16006586.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7889-96 [16204015.001]
  • [Cites] Cardiovasc Res. 2001 Feb 16;49(3):568-81 [11166270.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):843-50 [11157038.001]
  • [Cites] Int J Oncol. 2002 Jul;21(1):11-6 [12063543.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):327-37 [12538485.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] N Engl J Med. 2003 Jul 31;349(5):427-34 [12890841.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):721-32 [13130303.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] J Clin Pathol. 2004 Jul;57(7):773-5 [15220376.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] J Biol Chem. 1991 Jun 25;266(18):11947-54 [1711045.001]
  • [Cites] Cell. 1993 Mar 26;72(6):835-46 [7681362.001]
  • [Cites] Nat Med. 1995 Oct;1(10):1024-8 [7489357.001]
  • [Cites] Cancer Res. 1996 May 15;56(10):2299-301 [8625303.001]
  • [Cites] J Urol. 1997 Apr;157(4):1482-6 [9120987.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4593-9 [9377574.001]
  • [Cites] Lancet. 1999 Jan 2;353(9146):14-7 [10023944.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):7812-9 [15585612.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):133-41 [15625368.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):1011-27 [15585754.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):965-72 [15613696.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1855-61 [15870716.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5472-80 [16061863.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2530-40 [10561319.001]
  • (PMID = 16508632.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  • [Number-of-references] 31
  • [Other-IDs] NLM/ PMC2361396
  •  go-up   go-down


11. Roskoski R Jr: Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun; 2007 May 4;356(2):323-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
  • Sunitinib (SU-11248, Sutent) inhibits at least eight receptor protein-tyrosine kinases including vascular endothelial growth factor receptors 1-3 (VEGFR1-VEGFR3), platelet-derived growth factor receptors (PDGFRalpha and PDGFRbeta), stem cell factor receptor (Kit), Flt-3, and colony-stimulating factor-1 receptor (CSF-1R).
  • PDGFRbeta, which is found in pericytes that surround capillary endothelial cells, plays a pivotal role in stabilizing the vascular endothelium.
  • Renal cell cancers that have metastasized, or spread from the primary tumor, exhibit extensive vascularity, and sunitinib is approved for the treatment of these neoplasms.
  • Activating Kit mutations occur in about 85% of gastrointestinal stromal tumors and activating PDGFRalpha mutations occur in about 5% of these tumors.
  • Sunitinib is approved for the treatment of those tumors that are resistant to imatinib (STI-571, Gleevec), another Kit and PDGFRalpha protein-tyrosine kinase inhibitor.
  • [MeSH-minor] Animals. Antibodies, Monoclonal / pharmacology. Antibodies, Monoclonal, Humanized. Bevacizumab. Biological Availability. Humans. Mice. Protein Kinase Inhibitors / pharmacokinetics. Protein Kinase Inhibitors / pharmacology. Tumor Cells, Cultured

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367763.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Indoles; 0 / Protein Kinase Inhibitors; 0 / Pyrroles; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / sunitinib; 2S9ZZM9Q9V / Bevacizumab; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor
  •  go-up   go-down


12. Su X, Zhang L, Jin L, Ye J, Guan Z, Chen R, Guo T: Immunotherapy with cytokine-induced killer cells in metastatic renal cell carcinoma. Cancer Biother Radiopharm; 2010 Aug;25(4):465-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy with cytokine-induced killer cells in metastatic renal cell carcinoma.
  • Cytokine-induced killer (CIK) cells have shown antitumor activity against several tumor cells both in vitro and in vivo.
  • This study reports on the large-scale expansion of CIK cells and also present preliminary results from a pilot clinical trial.
  • Sixteen (16) patients with renal cell carcinoma (RCC), all of whom had metastases after radical nephrectomy and adjuvant therapy using interferon-alpha (IFN-alpha) and/or interleukin-2 (IL-2), were treated with CIK cells.
  • CIK cells were generated from peripheral blood mononuclear cells (PBMCs) and incubated in the presence of IFN-gamma followed by OKT3 and IL-2.
  • Treatment schedule consisted of two to three cycles of CIK cell infusions at an interval of 3 weeks.
  • A total of 46 infusions were administered to 16 metastatic RCC (mRCC) patients.
  • The median number of transferred cells per treatment was 6.7 x 10(9) (range, 2.5-12.3).
  • At a 60:1 effector-target cell ratio, CIK cells killed 51.4% and 32.1% of two human kidney tumor cell lines (293 and SK-RC-42), respectively.
  • After CIK cell infusion, the percentage of CD3(+), CD8(+), CD3(+)CD56(+), and NKG2D(+) cells and the intracellular products of two type 1 cytokines (IFN-gamma and tumor necrosis factor alpha) significantly increased in the patients' PBMCs.
  • Three (3) patients had complete response, 1 patient had partial response, and 6 patients had stable disease.
  • These results showed that adoptive CIK cell immunotherapy is a safe and effective treatment, which may have essential benefits for the improvement of the immunologic function in mRCC patients and play an important role in the treatment of mRCC.
  • [MeSH-major] Carcinoma, Renal Cell / therapy. Cytokine-Induced Killer Cells / immunology. Cytokines / pharmacology. Immunotherapy. Kidney Neoplasms / therapy. Liver Neoplasms / therapy. Lung Neoplasms / therapy


13. Hui GC, Tuncali K, Tatli S, Morrison PR, Silverman SG: Comparison of percutaneous and surgical approaches to renal tumor ablation: metaanalysis of effectiveness and complication rates. J Vasc Interv Radiol; 2008 Sep;19(9):1311-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of percutaneous and surgical approaches to renal tumor ablation: metaanalysis of effectiveness and complication rates.
  • PURPOSE: To determine the effectiveness and complication rates of ablation of renal cell carcinoma (RCC) performed with a percutaneous approach versus a surgical approach.
  • MATERIALS AND METHODS: A search performed on PubMed identified series of renal tumor ablations.
  • Keywords searched included "radiofrequency" (RF), "cryoablation", "cryosurgery", "cryotherapy", "ablation", "renal", "kidney", and "RCC".
  • Effectiveness was defined by the proportion of tumors without residual enhancement after one treatment session (ie, primary effectiveness) or after repeated treatments (ie, secondary effectiveness).
  • Differences were considered significant if the 95% CIs did not overlap.
  • CONCLUSIONS: Based on a metaanalysis, when ablating renal tumors, a percutaneous approach was safer than an open or laparoscopic approach and was equally effective.
  • However, more than one procedure was needed to treat the tumor completely.
  • [MeSH-major] Catheter Ablation / statistics & numerical data. Cryosurgery / statistics & numerical data. Kidney Neoplasms / epidemiology. Kidney Neoplasms / surgery. Postoperative Complications / epidemiology. Risk Assessment / methods


14. Song C, Jun SY, Hong JH, Ahn H: Transforming growth factor-beta downregulates interleukin-2-induced phosphorylation of signal transducer and activator of transcription 5 in human renal cell carcinoma. J Cancer Res Clin Oncol; 2007 Jul;133(7):487-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transforming growth factor-beta downregulates interleukin-2-induced phosphorylation of signal transducer and activator of transcription 5 in human renal cell carcinoma.
  • PURPOSE: We investigated signal transducer and activator of transcription-5 (STAT5) activation status in renal cell carcinoma (RCC) and the role of transforming growth factor-beta (TGF-beta) in the process.
  • METHODS: Twenty normal and RCC tissues were obtained from radical nephrectomy specimens for the assessment of expressions of phosphorylated STAT5 (p-STAT5) and TGF-beta1 (Western blot) and for localization and assessment of their relationship (immunohistochemical and immunofluorescence stains).
  • By using four RCC cell lines and four primary cultured cells, the effect of TGF-beta1 and/or interleukin-2 (IL-2) on the expressions of p-STAT5 were analyzed.
  • RESULTS: In RCC samples, expression of p-STAT5 was significantly reduced while expression of TGF-beta was enhanced compared with normal kidney tissues (P < 0.001 and P = 0.003, respectively).
  • P-STAT5 was observed almost exclusively in the nuclei of normal kidney tissues while TGF-beta was identified in the cytoplasm of cells of both tissues reflecting the Western results.
  • In both RCC cell lines and cells from primary cultures, treatment with TGF-beta or antibody did not significantly alter STAT5 activation.
  • CONCLUSIONS: STAT5 activation is suppressed in RCC compared with normal renal parenchyma.
  • It may be attributed to the RCC-derived TGF-beta which also interferes with IL-2-induced STAT5 pathway activation.
  • [MeSH-major] Carcinoma, Renal Cell / metabolism. Interleukin-2 / pharmacology. Kidney Neoplasms / metabolism. STAT5 Transcription Factor / metabolism. Transforming Growth Factor beta / pharmacology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4774-82 [15256446.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Nov;36(11):2120-4 [15313458.001]
  • [Cites] Urology. 2003 May;61(5):1072-7 [12736050.001]
  • [Cites] Cytokine. 2000 Jul;12(7):1084-91 [10880255.001]
  • [Cites] Urol Res. 2004 Oct;32(5):317-22 [15365652.001]
  • [Cites] J Immunol. 1999 Mar 1;162(5):2974-81 [10072548.001]
  • [Cites] Leukemia. 2001 Dec;15(12):1923-31 [11753614.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13897-902 [9391124.001]
  • [Cites] Lab Invest. 1997 May;76(5):739-49 [9166292.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):344-9 [12865928.001]
  • [Cites] J Immunol. 2001 Jul 1;167(1):553-61 [11418694.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2053-60 [15169792.001]
  • [Cites] J Clin Invest. 1993 Dec;92(6):2569-76 [7504687.001]
  • [Cites] Oncogene. 2005 Jan 27;24(5):746-60 [15592524.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5863-8 [16115927.001]
  • [Cites] J Immunol. 1997 Jul 1;159(1):175-83 [9200453.001]
  • (PMID = 17279417.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Interleukin-2; 0 / STAT5 Transcription Factor; 0 / Transforming Growth Factor beta
  •  go-up   go-down


15. Xu ZF, Xu HX, Xie XY, Liu GJ, Zheng YL, Lu MD: Renal cell carcinoma and renal angiomyolipoma: differential diagnosis with real-time contrast-enhanced ultrasonography. J Ultrasound Med; 2010 May;29(5):709-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma and renal angiomyolipoma: differential diagnosis with real-time contrast-enhanced ultrasonography.
  • OBJECTIVE: The purpose of this study was to evaluate the usefulness of contrast-enhanced ultrasonography (CEUS) in differentiating renal cell carcinoma (RCC) from renal angiomyolipoma (RAML).
  • METHODS: One hundred nineteen patients with 126 renal lesions (33 RAMLs and 93 RCCs) who had undergone CEUS were retrospectively studied.
  • The tumor echogenicity, enhancement patterns, and degree of enhancement at different phases were evaluated.
  • RESULTS: On CEUS, the features of wash-out from hyperenhancement or isoenhancement to hypoenhancement over time (observed in 3.0% of RAMLs and 71.0% of RCCs; P < .001), heterogeneous enhancement (observed in 12.1% of RAMLs and 74.2% of RCCs; P < .001), and an enhanced perilesional rim (observed in 3.0% of RAMLs and 79.6% of RCCs; P < .001) achieved significant difference between RCCs and RAMLs.
  • Early wash-out and heterogeneous enhancement or peritumoral rim enhancement yielded the highest diagnostic capability in differentiating RCC from RAML.
  • CONCLUSIONS: The CEUS features of early wash-out, heterogeneous enhancement, and an enhanced peritumoral rim highly suggest RCC, whereas homogeneous enhancement and prolonged enhancement are characteristic manifestations of RAML.
  • Contrast-enhanced ultrasonography is valuable in differentiating RCC from RAML.
  • [MeSH-major] Angiomyolipoma / ultrasonography. Carcinoma, Renal Cell / ultrasonography. Kidney Neoplasms / ultrasonography. Phospholipids. Sulfur Hexafluoride. Ultrasonography / methods
  • [MeSH-minor] Adult. Aged. Computer Systems. Contrast Media. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20427782.001).
  • [ISSN] 1550-9613
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


16. Hsieh CL, Peng CC, Cheng YM, Lin LY, Ker YB, Chang CH, Chen KC, Peng RY: Quercetin and ferulic acid aggravate renal carcinoma in long-term diabetic victims. J Agric Food Chem; 2010 Aug 25;58(16):9273-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quercetin and ferulic acid aggravate renal carcinoma in long-term diabetic victims.
  • It is hypothesized that phytoantioxidants (PAO) are beneficial only to the early-stage diabetes mellitus (DM) and will become ineffective once renopathy occurs.
  • The incidence of cataract (50%), injured glomerules, and renal cell carcinoma (RCC) was very common, among which the most severely affected involved the quercetin- and the FA-treated groups.
  • However, for quercetin, this can be attributted to (i) the prooxidant effect, (ii) the insulin-secretagogue bioactivity, and (iii) the competitive and noncompetitive inhibition on the O-methyltransferase to enhance the estradiol-induced tumorigenesis.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Coumaric Acids / adverse effects. Diabetes Mellitus, Experimental / complications. Kidney Neoplasms / pathology. Quercetin / adverse effects

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. FERULIC ACID .
  • Hazardous Substances Data Bank. QUERCETIN .
  • Hazardous Substances Data Bank. STREPTOZOTOCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20669956.001).
  • [ISSN] 1520-5118
  • [Journal-full-title] Journal of agricultural and food chemistry
  • [ISO-abbreviation] J. Agric. Food Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coumaric Acids; 5W494URQ81 / Streptozocin; 9IKM0I5T1E / Quercetin; AVM951ZWST / ferulic acid
  •  go-up   go-down


17. Srinivas S, Guardino AE: A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma. BJU Int; 2005 Sep;96(4):536-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma.
  • OBJECTIVE: To conduct a dose-finding trial using a single low dose and dose escalation of a higher dose of thalidomide in patients with metastatic renal cell carcinoma (RCC), and to evaluate the antineoplastic effectiveness of thalidomide as an anti-angiogenic agent on RCC.
  • PATIENTS AND METHODS: The 14 patients enrolled in the study had progressive measurable metastatic RCC and consented to participate.
  • RESULTS: Stable disease was achieved in six patients and was seen in both the low-dose and high-dose thalidomide groups.
  • The low-dose thalidomide regimen was better tolerated and patients survived longer than those on the high-dose regimen (16 vs 6 months, P = 0.04) CONCLUSION: The use of low-dose thalidomide in patients with metastatic RCC was well tolerated and they survived for longer than those on the high-dose regimen.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / drug therapy. Thalidomide / administration & dosage

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16104906.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


18. Funao K, Matsuyama M, Naganuma T, Kawahito Y, Sano H, Nakatani T, Yoshimura R: The cysteinylLT1 receptor in human renal cell carcinoma. Mol Med Rep; 2008 Mar-Apr;1(2):185-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cysteinylLT1 receptor in human renal cell carcinoma.
  • We investigated LTD4 receptor (cysteinylLT1 receptor, CysLT1R) expression in renal cell carcinoma (RCC), as well as the effect of the CysLT1R antagonist on cell proliferation in the RCC cell line.
  • CysLT1R expression was detected by immunohistochemistry and examined in RCC patients and normal kidney (NK) tissues.
  • The effect of the CysLT1R antagonist on RCC cell growth was examined by MTT assay.
  • Initially, only slight CysLT1R expression was detected in NK tissues, and marked CysLT1R expression in RCC tissues.
  • CysLT1R expression was higher in high-grade than in low-grade cancer.
  • Furthermore, the CysLT1R antagonist caused marked inhibition of RCC cells in a concentration- and time-dependent manner through early apoptosis.
  • To conclude, CysLT1R was induced in RCC and the results suggest that the CysLT1R antagonist may mediate the potent anti-proliferative effects of RCC cells.
  • Thus, CysLT1R may become a new target therapy in the treatment of RCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21479395.001).
  • [ISSN] 1791-2997
  • [Journal-full-title] Molecular medicine reports
  • [ISO-abbreviation] Mol Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


19. Rafique M: Nephrectomy: indications, complications and mortality in 154 consecutive patients. J Pak Med Assoc; 2007 Jun;57(6):308-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To gain information about the indications for and complications of conventional nephrectomy as practiced in a teaching hospital of Pakistan.
  • The indications for nephrectomy were divided into benign and malignant conditions.
  • RESULTS: Out of 154 nephrectomies, 118 (76.6%) were performed for benign condition and 36 (23%) for malignant etiology.
  • 53.3%) of the patients had kidneys removed due to renal stone.
  • Other conditions in this group included chronic pyelonephritis (20%), neglected ureteropelvic junction obstruction (16%), renal tuberculosis (7.6%) and iatrogenic (2.5%).
  • Thirty-six (23%) patients had nephrectomy for malignant conditions i.e. renal cell carcinoma.
  • Malignant tumors were more common in males while benign conditions necessitating nephrectomy were predominant in female patients.
  • Patients with benign conditions were much younger (mean age 32 years) than patients in malignant group (mean age 52.8 years).
  • Nephrectomy for malignant disease had a higher rate of complications (13.8%) than for benign conditions (7.6%).
  • Two patients, one in each group, died post-operatively and the overall 30-day mortality was 1.29% CONCLUSION: The mean age of the patients undergoing nephrectomy for benign and malignant conditions was lower than reported from western countries.
  • Renal stone related etiology was the major indication for nephrectomy.
  • Malignant renal tumours affected patients at a remarkably younger age and clear cell renal carcinoma was the predominant histological variety.
  • Nephrectomy for malignant conditions had a higher rate of complications than for benign conditions while there was no difference in the overall mortality.
  • [MeSH-major] Kidney Diseases / surgery. Nephrectomy / adverse effects. Nephrectomy / mortality

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629234.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


20. Zhao F, Qu Y, Tang B, Mao M, Mu D: [Telomerase reverse transcriptase expression and cell apoptosis during hypoxia ischemia brain damage in neonatal rats]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2010 May;24(5):588-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Telomerase reverse transcriptase expression and cell apoptosis during hypoxia ischemia brain damage in neonatal rats].
  • OBJECTIVE: To investigate the expression of telomerase reverse transcriptase (TERT) and cell apoptosis in neonatal rats with hypoxia ischemia brain damage (HIBD).
  • The right common carotid artery (CCA) was exposed and permanently ligated with a 7-0 silk suture through a midline cervical incision.
  • The apoptosis cells were detected with TUNEL staining method.
  • The TUNEL staining showed that the positive cells in hippocampus and cortical areas were increased at 4 hours after HI injury, significantly increased at 24-48 hours and maintained a high level at 72 hours.
  • However, there was few positive cells in the sham-operation group.
  • CONCLUSION: TERT could be induced by HI in neonatal rats, and might have a protective role in regulating the cell apoptosis in the neonatal HIBD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20540267.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


21. Renaud J, Yartsev S, Dar AR, Van Dyk J: Successful treatment of primary renal lymphoma using image guided helical tomotherapy. Can J Urol; 2009 Jun;16(3):4639-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of primary renal lymphoma using image guided helical tomotherapy.
  • PURPOSE: To describe a clinical pilot case of renal lymphoma successfully treated using helical tomotherapy, and to evaluate alternative hypofractionated treatment schedules and their potential applicability to future cases of renal cell carcinoma (RCC).
  • PATIENTS AND METHODS: An 82-year-old female patient with a large right perinephric mass encircling the lower pole of the right kidney was treated on the Hi-ART unit (TomoTherapy Inc.
  • Gross tumor volumes (GTVs) were outlined on every MVCT study.
  • Six alternative treatment schedules were investigated: 48 Gy in 4 and 3 fractions, and 60 Gy in 30, 5, 4 and 3 fractions, as possible clinical scenarios for RCC.
  • Normal tissue complication probability (NTCP) and tumor control probability (TCP) values were estimated for each scenario in the study.
  • NTCP and TCP estimates have shown that hypofractionated treatment schedules provide a much higher probability of local control, but the risk of tissue complication rises simultaneously.
  • CONCLUSIONS: Caution should be observed in high dose hypofractionated radiotherapy in right sided, whole kidney carcinoma due to increased risk of liver complication.
  • The accelerated treatment may however be justified by the significantly higher TCP rates for left sided kidney cases.
  • Further investigation of small renal tumors is needed to evaluate control rates, vasculopathy, and residual normal function.
  • [MeSH-major] Kidney Neoplasms / radiotherapy. Lymphoma / radiotherapy. Tomography, Spiral Computed

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19497170.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  •  go-up   go-down


22. Nishizawa M, Hirayama F, Matsuyama N, Tada K, Kaneko H, Watanabe M, Miura Y, Tsudo M: [Transfusion-related acute lung injury with anti-leukocyte antibodies identified both in patient's serum and in red cell concentrate]. Rinsho Ketsueki; 2009 Jan;50(1):16-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transfusion-related acute lung injury with anti-leukocyte antibodies identified both in patient's serum and in red cell concentrate].
  • We report a fatal case of transfusion-related acute lung injury (TRALI) with anti-leukocyte antibodies detected both in the patient's serum and in the causative red cell concentrate (RC-M.A.P).

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19225224.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / HLA Antigens
  •  go-up   go-down


23. Nogueira M, Kim HL: Molecular markers for predicting prognosis of renal cell carcinoma. Urol Oncol; 2008 Mar-Apr;26(2):113-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular markers for predicting prognosis of renal cell carcinoma.
  • Metastatic or recurrent renal cell carcinoma (RCC) carries a poor prognosis and long term survival is rare.
  • However, many small RCCs that are incidentally discovered have an indolent course even without treatment.
  • The variability in clinical outcome is a reflection of the underlying tumor biology.
  • Currently, clinical variables such as tumor stage and histologic grade are widely accepted surrogates for tumor-specific cellular and molecular processes.
  • We review expression array studies evaluating molecular signatures for predicting prognosis in patients with RCC and describe specific prognostic markers that have been validated in at least 50 cases of RCC.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312928.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 184
  •  go-up   go-down


24. Sáenz López P, Vázquez Alonso F, Romero JM, Carretero R, Tallada Buñuel M, Ruiz Cabello F, Cózar Olmo JM: [Polymorphisms in inflammatory response genes in metastatic renal cancer]. Actas Urol Esp; 2009 May;33(5):474-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Polymorphisms in inflammatory response genes in metastatic renal cancer].
  • [Transliterated title] Polimorfimos en genes de respuesta inflamatoria en cáncer renal metastásico.
  • Inflammation has been implicated as an etiological factor in different human cancers.
  • Allelic variations in the genes implicated in inflammation are candidates as genetic determinants or markers of renal carcinoma risk.
  • The present stud investigates whether polymorphisms of the genes that give rise to increases in the levels of proinflammatory cytokines and chemokines are associated with an increased risk of renal carcinoma.
  • To this effect, a number of case-control studies were designed to assess the correlation between renal carcinoma and polymorphisms IL10-1082 A/G (rs 1800896), IL10-592 A/C (rs 1800872), IL10-819 C/T (rs 1800871), IL10-1082 A/G, IL4-590 C/T (rs 2243250), TNF-A-308 A/G (rs 1800629), RANTES-403 G/A (rs 2107538), IL1-A-889 C/T (rs 1800587), MCP-1 2518 G/A (rs 1024611), CTLA-4/+49 A/G (rs 231775) and CTLA-4 CT60 A/G (rs 3087243) in 127 renal carcinoma patients and in 176 healthy subjects.
  • The results obtained in relation to cytokine polymorphism IL-10-1082 A/G indicate that AG heterozygosity status is the principal risk factor in relation to locally advanced or metastatic tumor stage and renal carcinoma.
  • In the case of the molecule CTLA4, the results obtained in renal cancer reveal an association between the polymorphisms of the CTLA-4 gene and an increased risk of developing renal cell carcinoma.
  • A high genotypic frequency of polymorphisms CTLA4/CT60-AA and CTLA4/A49G-AA is observed in patients with renal cell carcinoma versus the controls.
  • An association has been established between polymorphism CTLA4/CT60 and tumor grade in patients with renal cell carcinoma.
  • Logistic regression analysis has confirmed these data, demonstrating a high frequency of the AA genotype in patients with high-grade tumors.
  • The results obtained support the hypothesis that different genetic factors implicated in the regulation of adaptive immune responses, stromal cell composition and local cytokine production levels may be crucial elements in the modification of the clinicopathological parameters of renal carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / immunology. Kidney Neoplasms / genetics. Kidney Neoplasms / immunology. Polymorphism, Genetic
  • [MeSH-minor] Case-Control Studies. Chemokines / genetics. Cytokines / genetics. Humans. Inflammation / genetics. Interleukin-10 / genetics. Neoplasm Metastasis / genetics

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19658300.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Chemokines; 0 / Cytokines; 130068-27-8 / Interleukin-10
  •  go-up   go-down


25. Zada G, Ditty B, McNatt SA, McComb JG, Krieger MD: Surgical treatment of rathke cleft cysts in children. Neurosurgery; 2009 Jun;64(6):1132-7; author reply 1037-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Rathke cleft cysts (RCCs) are cystic epithelial lesions in the sellar and suprasellar regions that are often discovered incidentally.
  • Our aim was to review our experience with pediatric patients treated surgically for RCCs.
  • METHODS: A retrospective review was conducted of all patients treated surgically for RCCs at Childrens Hospital Los Angeles between 1999 and 2007 after approval by the institutional review board.
  • Clinical notes, operative reports, radiological studies, and pathology reports were reviewed.
  • RESULTS: Ten patients undergoing surgical treatment of an RCC were identified, making up 20% of the 51 patients with RCCs followed clinically over the same time period.
  • Patients requiring surgery presented with the following clinical symptoms: headache (8 patients, 80%), endocrine insufficiency (6 patients, 60%), meningitis followed by visual loss (1 patient, 10%), and incidental finding (1 patient, 10%).
  • Four patients had strictly sellar lesions, 4 patients had suprasellar extension of an RCC, and 2 patients had primarily suprasellar RCCs.
  • CONCLUSION: RCCs are an infrequent cause of symptoms in pediatric patients.
  • Fenestration and aspiration of the cyst are usually sufficient to achieve total resolution of symptoms and signs caused by RCCs.
  • Patient selection remains of paramount importance when considering surgery for pediatric patients with RCCs.
  • [MeSH-major] Central Nervous System Cysts / surgery. Craniotomy / methods. Microsurgery / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19487893.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Ficarra V, Novara G, Iafrate M, Cappellaro L, Bratti E, Zattoni F, Artibani W: Proposal for reclassification of the TNM staging system in patients with locally advanced (pT3-4) renal cell carcinoma according to the cancer-related outcome. Eur Urol; 2007 Mar;51(3):722-9; discussion 729-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proposal for reclassification of the TNM staging system in patients with locally advanced (pT3-4) renal cell carcinoma according to the cancer-related outcome.
  • OBJECTIVES: The optimal stratification of locally advanced renal cell carcinoma (RCC) is controversial, with the prognostic relevance of ipsilateral adrenal gland invasion and cranial extension of vena cava thrombosis being the most debatable issues.
  • We evaluated the prognosis of patients with locally advanced RCC and identified a new model to stratify their outcome.
  • MATERIALS AND METHODS: We analyzed the data of 227 patients who had undergone partial or radical nephrectomy for pT3-4 RCC at two academic centers between 1986 and 2002.
  • RESULTS: At a median follow-up of 29 mo, we censored 108 (47.6%) cancer-related deaths.
  • On univariate analysis, the 2002 T stage was not statistically significant.
  • According to cancer-related outcome, we identified three subgroups of patients with different prognoses: pT3a(n): tumors with perirenal fat invasion or renal vein thrombosis or thrombosis within the vena cava below the diaphragm; pT3b(n): tumors with renal vein thrombosis or thrombosis within the vena cava below the diaphragm and concomitant perirenal fat invasion; pT4(n): adrenal gland or Gerota fascia invasion or thrombosis within the vena cava above the diaphragm.
  • The new reclassification was an independent predictive variable on multivariate analysis, as well as the pathologic lymph node stage.
  • CONCLUSIONS: The 2002 version of TNM of locally advanced RCC did not stratify patient outcome.
  • The present study suggests the possibility of reclassifying pT3-4 RCC into three categories capable of predicting cancer-specific survival, regardless of all other prognostic factors.
  • [MeSH-major] Carcinoma, Renal Cell / classification. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / classification. Kidney Neoplasms / pathology


27. Transperitoneal laparoscopic right radical nephrectomy for renal cell carcinoma and end-stage renal disease: a case report. Cases J; 2009 Nov 18;2:200
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transperitoneal laparoscopic right radical nephrectomy for renal cell carcinoma and end-stage renal disease: a case report.
  • Nephron-sparing surgery (partial nephrectomy) results are similar to those of radical nephrectomy for small (<4 cm) renal tumors.
  • However, in patients with end-stage renal disease, radical nephrectomy emerges as a more efficient treatment for localized renal cell cancer.
  • The objective of the present study was to present a case of a patient under hemodialysis who was submitted to LRN for a small renal mass and discuss the current issues concerning this approach.
  • It appears that radical nephrectomy should be the standard treatment in dialysis patients even for small tumors.
  • The laparoscopic technique is associated with acceptable cancer-specific survival and recurrence rate along with shorter hospital stay, less postoperative pain and earlier return to normal activities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2000 Feb;163(2):437-41 [10647649.001]
  • [Cites] Urology. 2003 Dec;62(6):1018-23 [14665347.001]
  • [Cites] J Urol. 2004 Jun;171(6 Pt 1):2181-5, quiz 2435 [15126781.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Endourol. 2005 Sep;19(7):803-7 [16190832.001]
  • [Cites] Int J Urol. 2006 Aug;13(8):1045-8 [16903927.001]
  • [Cites] Urology. 2007 Feb;69(2):226-9 [17275073.001]
  • [Cites] J Urol. 2005 Oct;174(4 Pt 1):1222-5 [16145374.001]
  • (PMID = 20062705.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Fujibayashi S, Neo M, Nakamura T: Palliative dual iliac screw fixation for lumbosacral metastasis. Technical note. J Neurosurg Spine; 2007 Jul;7(1):99-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors describe their surgical technique for secure iliac screw placement and the clinical results obtained in five patients with metastatic spinal disease.
  • All patients in this study underwent palliative operations with dual iliac screw fixation between April 1999 and October 2002, and the clinical and radiological findings were assessed.
  • The metastases were from renal cell carcinomas in two patients, lung cancer in two, and a paraganglioma in one patient.

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633497.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Liang S, Gong F, Zhao X, Wang X, Shen G, Xu Y, Yang H, Ruan X, Wei Y: Prokaryotic expression, purification of a new tumor-relative protein FAM92A1-289 and its characterization in renal cell carcinoma. Cancer Lett; 2009 Apr 8;276(1):81-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prokaryotic expression, purification of a new tumor-relative protein FAM92A1-289 and its characterization in renal cell carcinoma.
  • In order to study the characterization of a new tumor-relative FAM92A1-289 protein, we first constructed plasmid FAM92A1-pQE30 for fusion expression in Escherichia coli.
  • Furthermore, the expression and cell localization of FAM92A1-289 by immunohistochemistry using our self-prepared polyclonal antibody showed it was expressed in cytoplasm of renal carcinoma.
  • FAM92A1-289 mRNA was expressed in 2 of 10 kidney tissues and in 6 of 12 primary renal tumors.
  • FAM92A1-289 can promote cell growth in vitro and in vivo by colony formation and mouse xenograft assay.
  • Our present data indicated FAM92A1-289 is a new tumor-related gene with oncogenic potentials to probably play roles in renal carcinogenesis.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Gene Expression. Kidney Neoplasms / genetics. Proteins / genetics. Proteins / metabolism

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19059705.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / FAM92A1 protein, human; 0 / Proteins; 0 / RNA, Messenger; 0 / Recombinant Fusion Proteins
  •  go-up   go-down


30. Kabutan K, Taniguchi M: [Anesthetic management of radical nephrectomy using cardiopulmonary bypass in patients with vena caval or atrial extension of renal cell carcinoma]. Masui; 2005 Aug;54(8):881-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anesthetic management of radical nephrectomy using cardiopulmonary bypass in patients with vena caval or atrial extension of renal cell carcinoma].
  • We experienced three cases of anesthesia for radical nephrectomy using cardiopulmonary bypass in patients with vena caval or atrial extension of renal cell carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Cardiopulmonary Bypass. Heart Neoplasms / pathology. Kidney Neoplasms / surgery. Nephrectomy / methods. Vascular Neoplasms / pathology. Venae Cavae
  • [MeSH-minor] Aged. Fatal Outcome. Heart Atria. Humans. Intraoperative Complications / prevention & control. Male. Middle Aged. Neoplasm Invasiveness. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16104541.001).
  • [ISSN] 0021-4892
  • [Journal-full-title] Masui. The Japanese journal of anesthesiology
  • [ISO-abbreviation] Masui
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


31. Ranganathan S: Pediatric Renal Neoplasms. Surg Pathol Clin; 2009 Mar;2(1):27-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric Renal Neoplasms.
  • Renal tumors in childhood consist of a diverse group of tumors ranging from the most common Wilms' tumor, to the uncommon and often fatal rhabdoid tumor.
  • Diagnosis is based on morphologic features and aided by ancillary techniques such as immunohistochemistry and cytogenetics.
  • Molecular techniques have helped identify a group of pediatric renal cell carcinomas that have specific translocations, called translocation-associated carcinomas.
  • Differential diagnosis of the various tumors is discussed.
  • Pathogenesis and nephroblastomatosis, the precursor lesions of Wilms tumor, also are discussed briefly, as are the handling of these tumor specimens and prognostic factors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier Inc. All rights reserved.
  • (PMID = 26838099.001).
  • [ISSN] 1875-9181
  • [Journal-full-title] Surgical pathology clinics
  • [ISO-abbreviation] Surg Pathol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Clear cell sarcoma / Malignant rhabdoid tumor / Mesoblastic nephroma / Metanephric tumors / Nephrogenic rests / Translocation carcinomas / Wilms' tumor
  •  go-up   go-down


32. Prenen H, Gil T, Awada A: New therapeutic developments in renal cell cancer. Crit Rev Oncol Hematol; 2009 Jan;69(1):56-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New therapeutic developments in renal cell cancer.
  • Metastatic renal cell cancer is associated with a poor prognosis and is very resistant to conventional cytotoxic chemotherapy.
  • Progress in the understanding of molecular biology and pathogenesis of renal cell cancer has been translated into the development of new therapeutic strategies.
  • The recent approval of sunitinib, sorafenib, temsirolimus and bevacizumab in combination with IFN-alpha has revolutionized the management of renal cell carcinoma.
  • In this review, we describe the status of current treatment strategies for metastatic renal cell cancer and we focus on the new compounds including targeted therapy such as new anti-angiogenic and mTOR inhibitors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / immunology. Kidney Neoplasms / drug therapy. Kidney Neoplasms / immunology
  • [MeSH-minor] Cancer Vaccines / immunology. Humans. Immunotherapy


33. Courtney KD, Choueiri TK: Optimizing recent advances in metastatic renal cell carcinoma. Curr Oncol Rep; 2009 May;11(3):218-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimizing recent advances in metastatic renal cell carcinoma.
  • The past few years have seen dramatic advances in the treatment of metastatic renal cell carcinoma (RCC).
  • Dissection of the molecular pathways that regulate proliferation, apoptosis, and angiogenesis has led to the development of targeted therapies such as the receptor tyrosine kinase inhibitors sunitinib and sorafenib, the anti-vascular endothelial growth factor antibody bevacizumab, and a class of rapamycin analogues including everolimus and temsirolimus.
  • Each of these agents has demonstrated clinical efficacy in patients with metastatic RCC.
  • The challenge before us is to expand on these successes by identifying which patients will best respond to these targeted therapies, optimizing the proper combination or sequence of available therapies, developing agents with improved side effect profiles, and identifying novel therapeutic targets to expand our armamentarium in the treatment of RCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2004 Sep 15;10 (18 Pt 2):6290S-5S [15448019.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2477-90 [16339096.001]
  • [Cites] Clin Genitourin Cancer. 2009 Jan;7(1):24-7 [19213664.001]
  • [Cites] Clin Genitourin Cancer. 2007 Sep;5(6):379-85 [17956710.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14 (20):6674-82 [18927310.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] Nat Med. 2006 Jan;12 (1):122-7 [16341243.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):832-41 [15681528.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1456-64 [16424173.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Cell Cycle. 2008 Oct;7(19):2987-90 [18818511.001]
  • [Cites] Lancet Oncol. 2007 Nov;8(11):975-84 [17959415.001]
  • [Cites] Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006017 [18425931.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2516-24 [16757724.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14 ):2954-63 [15254063.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1432-9 [19224847.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):965-72 [15613696.001]
  • [Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]
  • [Cites] Future Oncol. 2008 Feb;4(1):85-92 [18241003.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2530-40 [10561319.001]
  • [Cites] Mol Cancer. 2006 Nov 03;5:56 [17083723.001]
  • [Cites] Br J Cancer. 2008 Oct 21;99(8):1197-203 [18797463.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):543-50 [17577222.001]
  • [Cites] Cancer Cell. 2008 Jul 8;14 (1):90-102 [18598947.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Jun;8(6):887-93 [18533798.001]
  • [Cites] Lancet. 1999 Jan 2;353(9146):14-7 [10023944.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):289-96 [11773181.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16484-9 [18948595.001]
  • [Cites] Lancet. 2007 Dec 22;370(9605):2103-11 [18156031.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):688-96 [7884429.001]
  • [Cites] J Urol. 2008 Sep;180(3):860-5; discussion 865-6 [18635227.001]
  • [Cites] Lancet. 2008 Aug 9;372(9637):449-56 [18653228.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5422-8 [18936475.001]
  • [Cites] Oncologist. 2008 Oct;13(10 ):1084-96 [18838439.001]
  • [Cites] Oncology (Williston Park). 2008 Apr 15;22(4):388-96; discussion 396, 402-3, 476 passim [18472614.001]
  • [Cites] Cancer. 2007 Dec 1;110(11):2468-77 [17932908.001]
  • [Cites] Nature. 2003 Sep 18;425(6955):307-11 [13679920.001]
  • [Cites] Oncology (Williston Park). 2007 Sep;21(10):1175-80; discussion 1184, 1187, 1190 [17926797.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):16-24 [16330672.001]
  • [Cites] Semin Oncol. 2006 Oct;33(5):583-7 [17045087.001]
  • [Cites] Oncogene. 2008 Sep 18;27(41):5497-510 [18794884.001]
  • (PMID = 19336014.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Number-of-references] 49
  •  go-up   go-down


34. Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D, Stanbridge E, Atkins M: Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer; 2007 Sep;5(6):379-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.
  • PURPOSE: Similar to other molecularly targeted agents, temsirolimus, an inhibitor of mammalian target of rapamycin, has shown promising activity in advanced renal cell carcinoma.
  • However, only a subset of patients appears to derive significant tumor responses.
  • In an effort to identify potential predictors of response to temsirolimus, tumor samples from a subset of patients within a randomized phase II trial of temsirolimus in advanced renal cell carcinoma were studied.
  • Expression levels were correlated with objective response (partial response [PR], minor response [MR]) and clinical benefit (PR, MR, SD>or=4 cycles) to temsirolimus.
  • RESULTS: Tissue specimens were obtained from 20 patients who were evaluable for both tumor response and staining for phospho-S6 and carbonic anhydrase IX.
  • Five patients achieved an objective response (1 PR/4 MRs) to temsirolimus.
  • No patient without high expression of either phospho-S6 or pAkt experienced an objective tumor response.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Sirolimus / analogs & derivatives
  • [MeSH-minor] Antigens, Neoplasm / metabolism. Carbonic Anhydrases / metabolism. Clinical Trials, Phase II as Topic. Female. Humans. Immunoenzyme Techniques. Male. Mutation / genetics. PTEN Phosphohydrolase / metabolism. Phosphorylation. Protein Kinases / drug effects. Proto-Oncogene Proteins c-akt / metabolism. Randomized Controlled Trials as Topic. TOR Serine-Threonine Kinases. Von Hippel-Lindau Tumor Suppressor Protein / genetics. Von Hippel-Lindau Tumor Suppressor Protein / metabolism

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17956710.001).
  • [ISSN] 1558-7673
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50-CA 10194
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Protein Kinase Inhibitors; 624KN6GM2T / temsirolimus; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


35. Neuzillet Y, Lechevallier E: [Renal oncocytoma]. Prog Urol; 2006 Apr;16(2):105-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal oncocytoma].
  • Due to its nonspecific clinical and radiological features, renal oncocytoma is usually diagnosed on the operative specimen.
  • Histological confirmation of the diagnosis is based on the distinction between oncocytoma and renal cell carcinoma (RCC), which can be difficult.
  • Description of cases in which RCC and oncocytoma are present in the same tumour and the hypothesis of a link between oncocytoma and RCC further complicate the diagnosis of this tumour by the urologist.
  • The authors reviewed the management of tumours suspected to be oncocytoma based on a review of the international literature concerning the diagnosis, natural history and treatment of renal oncocytoma.
  • [MeSH-major] Adenoma, Oxyphilic. Kidney Neoplasms

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16734229.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 88
  •  go-up   go-down


36. Frigo DE, Basu A, Nierth-Simpson EN, Weldon CB, Dugan CM, Elliott S, Collins-Burow BM, Salvo VA, Zhu Y, Melnik LI, Lopez GN, Kushner PJ, Curiel TJ, Rowan BG, McLachlan JA, Burow ME: p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1. Mol Endocrinol; 2006 May;20(5):971-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1.
  • Here, we demonstrate that the p38 MAPK stimulates both ERalpha- and ERbeta-mediated transcription in MCF-7 breast carcinoma, Ishikawa endometrial adenocarcinoma, and human embryonic kidney 293 cells.
  • We show for the first time using pharmacological and molecular techniques that the p160 coactivator glucocorticoid receptor-interacting protein 1 (GRIP1) is phosphorylated and potentiated by the p38 MAPK signaling cascade in vitro and in vivo.
  • The C terminus of GRIP1 was also demonstrated to contain a p38-responsive region.
  • [MeSH-major] Estrogen Receptor alpha / metabolism. Estrogen Receptor beta / metabolism. Nuclear Receptor Coactivator 2 / metabolism. Transcription, Genetic. p38 Mitogen-Activated Protein Kinases / metabolism
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation. Estrogens / pharmacology. Humans. Imidazoles / pharmacology. MAP Kinase Kinase 6 / metabolism. Phosphorylation. Protein Kinase Inhibitors / pharmacology. Pyridines / pharmacology

  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410316.001).
  • [ISSN] 0888-8809
  • [Journal-full-title] Molecular endocrinology (Baltimore, Md.)
  • [ISO-abbreviation] Mol. Endocrinol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK059389; United States / PHS HHS / / R06/CCR419466-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Estrogens; 0 / Imidazoles; 0 / NCOA2 protein, human; 0 / Nuclear Receptor Coactivator 2; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / RWJ 67657; EC 2.7.1.- / MAP2K6 protein, human; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 2.7.12.2 / MAP Kinase Kinase 6
  •  go-up   go-down


37. Ponti G, Luppi G, Losi L, Giannetti A, Seidenari S: Leser-Trélat syndrome in patients affected by six multiple metachronous primitive cancers. J Hematol Oncol; 2010;3:2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leser-Trélat syndrome in patients affected by six multiple metachronous primitive cancers.
  • Leser-Trélat syndrome is characterized by the eruptive appearance of multiple seborrheic keratoses in association with underlying malignant disease.
  • Usually, the sign of Leser-Trélat is associated with adenocarcinoma, most frequently of the colon, breast, or stomach, but also of the lung, kidney, liver, and pancreas.
  • Herein, we present a case that we believe is the first report of the sign of Leser-Trélat in association with occult gastric adenocarcinoma and the anamnestic oncologic history of five other multiple primitive cancers.
  • Epidermal growth factor receptor (EGFR) immunohistochemical expression analysis of multiple seborrheic keratoses revealed an intense membranous staining in the basal keratinocytes and in all the upper epidermal layers.
  • Patients with the sign of Leser-Trélat should undergo a diagnostic screening programme for malignant disease along with patients with known Leser-Trélat syndrome who present with a recent acute and florid eruption of their seborrheic keratoses.
  • [MeSH-major] Adenocarcinoma / diagnosis. Intestinal Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis. Neoplastic Syndromes, Hereditary / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Humans. Keratosis, Seborrheic / complications. Keratosis, Seborrheic / diagnosis. Male

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1992 Jun;26(6):947-50 [1535080.001]
  • [Cites] J Med Genet. 2005 Nov;42(11):801-10 [15958502.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):980-7 [16321766.001]
  • [Cites] Lancet Oncol. 2008 May;9(5):462-72 [18452857.001]
  • [Cites] Clin Exp Dermatol. 1988 May;13(3):177-9 [2977576.001]
  • [Cites] Acta Derm Venereol. 1991;71(2):166-9 [1675530.001]
  • [Cites] J Am Acad Dermatol. 2000 Aug;43(2 Pt 2):386-90 [10901731.001]
  • [Cites] N Engl J Med. 1987 Dec 17;317(25):1582-7 [2825016.001]
  • [Cites] Aust Fam Physician. 2009 Jul;38(7):498-505 [19575068.001]
  • (PMID = 20064244.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2820021
  •  go-up   go-down


38. Li L, Yao JL, di Sant'Agnese PA, Bourne PA, Picken MM, Young AN, Shen SS, Huang J: Expression of claudin-7 in benign kidney and kidney tumors. Int J Clin Exp Pathol; 2008;1(1):57-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of claudin-7 in benign kidney and kidney tumors.
  • Expression of claudin-7 was increased in chromophobe renal cell carcinoma in a recent oligonucleotide microarray study.
  • We studied the expression of claudin-7 in benign and neoplastic kidneys by immunohistochemical staining.
  • Chromophobe renal cell carcinoma was positive for claudin-7 expression in 100% (36/36) of cases, while papillary renal cell carcinoma, oncocytoma and clear cell renal cell carcinoma were positive in 90% (71/80), 45% (21/47) and 7% (7/98) of the cases, respectively.
  • Differential expression of Claudin-7 in different types of renal cell neoplasms can be useful in their differential diagnosis, particularly when used in a panel of markers.
  • In addition, results from this study support previous reports of distal nephron origin for chromophobe renal cell carcinoma and oncocytoma.
  • The data also suggest that, as far as claudin-7 expression is concerned, papillary renal cell carcinoma may be more closely related to the distal nephron, rather than the proximal nephron.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Renal Physiol. 2006 Dec;291(6):F1157-68 [16684922.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1745-54 [12000726.001]
  • [Cites] Hum Pathol. 2006 Jun;37(6):698-703 [16733210.001]
  • [Cites] ScientificWorldJournal. 2006;6:502-11 [16648909.001]
  • [Cites] Hum Pathol. 2006 May;37(5):569-77 [16647955.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):428-34 [16328347.001]
  • [Cites] FEBS Lett. 2006 Feb 6;580(3):923-31 [16427635.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2477-90 [16339096.001]
  • [Cites] Cytopathology. 2005 Aug;16(4):193-8 [16048505.001]
  • [Cites] Am J Pathol. 2005 Aug;167(2):577-84 [16049341.001]
  • [Cites] J Mol Diagn. 2005 May;7(2):206-18 [15858144.001]
  • [Cites] Clin Lab Med. 2005 Jun;25(2):247-57 [15848735.001]
  • [Cites] Histopathology. 2005 May;46(5):551-60 [15842637.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):53-9 [15790437.001]
  • [Cites] Pediatr Res. 2005 Mar;57(3):453-7 [15585672.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1531-6 [15619213.001]
  • [Cites] Histopathology. 2004 Dec;45(6):593-602 [15569050.001]
  • [Cites] Kidney Int. 1999 Oct;56(4):1606-22 [10504517.001]
  • [Cites] J Am Soc Nephrol. 2002 Apr;13(4):875-86 [11912246.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):281-91 [11859199.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):68-79 [11823975.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7878-81 [11691807.001]
  • [Cites] Am J Physiol Renal Physiol. 2001 Nov;281(5):F966-74 [11592954.001]
  • [Cites] Gastroenterology. 2001 Feb;120(2):411-22 [11159882.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1247-56 [10976699.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):604-14 [10931460.001]
  • [Cites] Mod Pathol. 1997 Jun;10(6):537-44 [9195569.001]
  • [Cites] Am J Surg Pathol. 1995 Nov;19(11):1245-56 [7573686.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;56(4):237-45 [2565618.001]
  • [Cites] Am J Surg Pathol. 1982 Oct;6(7):655-63 [7180965.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121(6):878-83 [15198361.001]
  • [Cites] Am J Physiol Renal Physiol. 2004 Jun;286(6):F1063-71 [14722018.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):676-8 [15105658.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6265-71 [14559813.001]
  • [Cites] Am J Surg Pathol. 2004 Jan;28(1):69-76 [14707866.001]
  • [Cites] Arch Pathol Lab Med. 2003 Sep;127(9):1176-81 [12946227.001]
  • [Cites] Oncogene. 2003 Apr 3;22(13):2021-33 [12673207.001]
  • [Cites] Oncogene. 2003 Feb 13;22(6):847-52 [12584564.001]
  • [Cites] Kidney Int. 2002 Aug;62(2):476-87 [12110008.001]
  • [Cites] Nephrol Dial Transplant. 2006 Sep;21(9):2391-8 [16766545.001]
  • (PMID = 18784823.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2480537
  • [Keywords] NOTNLM ; chromophobe / claudin-7 / clear cell / kidney / neoplasm / oncocytoma / papillary
  •  go-up   go-down


39. Zheng JN, Ma TX, Cao JY, Sun XQ, Chen JC, Li W, Wen RM, Sun YF, Pei DS: Knockdown of Ki-67 by small interfering RNA leads to inhibition of proliferation and induction of apoptosis in human renal carcinoma cells. Life Sci; 2006 Jan 11;78(7):724-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Knockdown of Ki-67 by small interfering RNA leads to inhibition of proliferation and induction of apoptosis in human renal carcinoma cells.
  • To investigate the effect of small-interfering RNA (siRNA) targeted against Ki-67, which is an attractive molecular target for cancer therapy, on inhibiting Ki-67 expression and cell proliferation in human renal carcinoma cells (HRCCs), siRNAs were used to inhibit the expression of Ki-67 in HRCCs.
  • TUNEL assay was used to measure the apoptosis of carcinoma cells.
  • Results of RT-PCR and in situ hybridization demonstrated reduction of Ki-67 mRNA expression in Ki-67 siRNAs treated 786-0 cells.
  • Similar reduction in Ki-67 protein measured by Western blot and immunocytochemistry was observed in cells transfected with Ki-67 siRNA.
  • Ki-67-siRNA treatment of HRCCs resulted in specific inhibition of proliferation and increased apoptotic cell death.
  • From these findings we conclude that inhibition of Ki-67 expression by siRNA may be a reasonable approach in renal cancer therapy.
  • [MeSH-major] Apoptosis / physiology. Carcinoma / metabolism. Gene Silencing / physiology. Ki-67 Antigen / metabolism. Kidney Neoplasms / metabolism. RNA, Small Interfering / metabolism
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Humans. In Situ Hybridization. In Situ Nick-End Labeling. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transfection

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16111722.001).
  • [ISSN] 0024-3205
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / RNA, Messenger; 0 / RNA, Small Interfering
  •  go-up   go-down


40. Kwak C, Park YH, Kim IY, Moon KC, Ku JH: Expression of bone morphogenetic proteins, the subfamily of the transforming growth factor-beta superfamily, in renal cell carcinoma. J Urol; 2007 Sep;178(3 Pt 1):1062-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of bone morphogenetic proteins, the subfamily of the transforming growth factor-beta superfamily, in renal cell carcinoma.
  • PURPOSE: We investigated the potential expression of bone morphogenetic proteins, including bone morphogenetic protein-4, 6 and 7, the largest subfamily of the transforming growth factor-beta superfamily, in patients with renal cell carcinoma and identified its potential prognostic value in terms of clinical outcome.
  • MATERIALS AND METHODS: Immunohistochemical staining of paraffin sections for bone morphogenetic protein was performed in 185 cases of renal cell carcinoma using a streptavidin-peroxidase procedure.
  • RESULTS: The positive rate of bone morphogenetic protein-4, 6 and 7 expression in renal cell carcinoma was 44.3%, 20.0% and 34.1%, respectively.
  • No statistically significant association was observed between bone morphogenetic protein immunoreactivity and age, Eastern Cooperative Oncology Group performance status and T stage.
  • The bone morphogenetic protein expression rate in nonclear types including chromophobe or papillary type was higher than that in the clear cell type (each p <0.001).
  • Disease-free survival was higher in patients with bone morphogenetic protein-7 expression than in those without expression (log rank test for trend p = 0.0273).
  • In addition, our findings suggest that bone morphogenetic protein-7 expression may be considered a new prognostic factor in renal cell carcinoma.
  • [MeSH-major] Bone Morphogenetic Proteins / metabolism. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / metabolism
  • [MeSH-minor] Bone Morphogenetic Protein 4. Bone Morphogenetic Protein 6. Bone Morphogenetic Protein 7. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17644140.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BMP4 protein, human; 0 / BMP6 protein, human; 0 / BMP7 protein, human; 0 / Bone Morphogenetic Protein 4; 0 / Bone Morphogenetic Protein 6; 0 / Bone Morphogenetic Protein 7; 0 / Bone Morphogenetic Proteins
  •  go-up   go-down


41. Dall'Oglio MF, Ribeiro-Filho LA, Antunes AA, Crippa A, Nesrallah L, Gonçalves PD, Leite KR, Srougi M: Microvascular tumor invasion, tumor size and Fuhrman grade: a pathological triad for prognostic evaluation of renal cell carcinoma. J Urol; 2007 Aug;178(2):425-8; discussion 428
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microvascular tumor invasion, tumor size and Fuhrman grade: a pathological triad for prognostic evaluation of renal cell carcinoma.
  • PURPOSE: The biological behavior and clinical outcome of renal cell carcinoma are difficult to predict.
  • MATERIALS AND METHODS: We studied 230 patients with renal cell carcinoma (stages T(1-4) N(x) M(0)) who underwent radical nephrectomy and/or nephron sparing surgery, and were followed for a median of 48 months (range 3 to 140).
  • Univariate and multivariate analyses were performed, and the influence of clinical presentation, histological tumor size, tumor grade, lymph node involvement and microvascular tumor invasion on disease-free and cancer specific survival curves was determined.
  • A composition model based on independent prognostic variables was then created to stratify tumors into low, intermediate and high risk of progression.
  • RESULTS: The tumor recurrence rate was 17% (39 of 230) and the cancer specific mortality rate was 13% (31 of 230).
  • Multivariate analyses determined that microvascular tumor invasion, tumor grade and tumor size were the only independent prognostic factors.
  • Disease-free survival rates for low, intermediate and high risk tumors were 94.7%, 56.8% and 13.1%, respectively.
  • Cancer specific survival rates were 94.7%, 61.7% and 32.0%, respectively.
  • CONCLUSIONS: Tumor size, Fuhrman grade and microvascular tumor invasion are strong and independent predictors of survival of patients with renal cell carcinoma.
  • Risk assessment and stratification based on this triad of pathological features may allow better individualization of followup schedules and trials of adjuvant treatment for patients with renal cell carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Microcirculation / pathology. Neovascularization, Pathologic / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Disease-Free Survival. Female. Humans. Kidney / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Nephrectomy. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Urol. 2008 Feb;5(2):74-5 [18059390.001]
  • (PMID = 17561167.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Danilin S, Sourbier C, Thomas L, Rothhut S, Lindner V, Helwig JJ, Jacqmin D, Lang H, Massfelder T: von Hippel-Lindau tumor suppressor gene-dependent mRNA stabilization of the survival factor parathyroid hormone-related protein in human renal cell carcinoma by the RNA-binding protein HuR. Carcinogenesis; 2009 Mar;30(3):387-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] von Hippel-Lindau tumor suppressor gene-dependent mRNA stabilization of the survival factor parathyroid hormone-related protein in human renal cell carcinoma by the RNA-binding protein HuR.
  • We have shown that parathyroid hormone-related protein (PTHrP) is a survival factor for human renal cell carcinoma (RCC) and that its expression is negatively regulated by the von Hippel-Lindau (VHL) tumor suppressor gene at the level of messenger RNA (mRNA) stability, as observed for tumor growth factors (TGFs).
  • Our goals were to analyze the alternative splicing of PTHrP mRNA in human RCC and from these results to identify VHL/hypoxia-induced factor (HIF) system-regulated mRNA-binding proteins involved in PTHrP mRNA stability.
  • We used: (i) a panel of human RCC cells expressing or not VHL;.
  • (ii) VHL-deficient 786-0 cells transfected with active or inactive VHL and (iii) human RCC samples and corresponding normal tissues.
  • By quantitative real-time reverse transcription-polymerase chain reaction analysis, the 141 PTHrP mRNA isoform was found to be predominant in all cells and tumors (80%).
  • In cells transfected with VHL, the expressions of all isoforms were decreased by 50%.
  • The protein having an apparent molecular weight of 30 kDa was identified by western blot as HuR, a RNA-binding protein with stabilizing functions on various mRNA coding for proteins important in malignant transformation including vascular endothelial growth factor and TGF-beta.
  • PTHrP expression studies confirmed the involvement of HuR in PTHrP upregulation in this disease.
  • Common mRNA-binding proteins regulated by the VHL/HIF system may constitute new therapeutic opportunities against human RCC that remains refractory to therapies.
  • [MeSH-major] Antigens, Surface / metabolism. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / metabolism. Parathyroid Hormone-Related Protein / metabolism. RNA Stability / physiology. RNA, Messenger / metabolism. RNA-Binding Proteins / metabolism. Von Hippel-Lindau Tumor Suppressor Protein / physiology
  • [MeSH-minor] Alternative Splicing. Cell Line, Tumor. ELAV Proteins. ELAV-Like Protein 1. Humans. Protein Binding

  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19056930.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / ELAV Proteins; 0 / ELAV-Like Protein 1; 0 / ELAVL1 protein, human; 0 / Parathyroid Hormone-Related Protein; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


43. McRoberts RJ, Beard D, Walsh TS: A study of blood product use in patients with major trauma in Scotland: analysis of a major trauma database. Emerg Med J; 2007 May;24(5):325-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 27.4% of patients received > or =8 units of red cell concentrate (RCC) within the first 24 h of hospitalisation.
  • Of these, 35 patients would require > or =8 units of RCC within the first 24 h.
  • Of these 67 patients, an estimated 35 patients (28 of whom had a blunt form of trauma) require > or =8 units of RCC during the first 24 h in hospital.

  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • MedlinePlus Health Information. consumer health - Wounds and Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Trauma. 2002 Aug;53(2):291-5; discussion 295-6 [12169936.001]
  • [Cites] J Trauma. 2003 May;54(5):898-905; discussion 905-7 [12777902.001]
  • [Cites] Blood Coagul Fibrinolysis. 2003 Jun;14 Suppl 1:S35-8 [14567534.001]
  • [Cites] Blood Coagul Fibrinolysis. 2003 Dec;14(8):713-7 [14614349.001]
  • [Cites] Crit Care Med. 2004 Jan;32(1):39-52 [14707558.001]
  • [Cites] Transfusion. 2006 Jun;46(6):919-33 [16734808.001]
  • [Cites] Unfallchirurg. 2004 Jul;107(7):563-74 [15179555.001]
  • [Cites] Arch Surg. 1998 Sep;133(9):947-52 [9749845.001]
  • [Cites] Emerg Med J. 2005 Jan;22(1):60-3 [15611550.001]
  • [Cites] J Trauma. 2005 Jul;59(1):8-15; discussion 15-8 [16096533.001]
  • [Cites] Transfusion. 2004 Jun;44(6):809-13 [15157244.001]
  • (PMID = 17452697.001).
  • [ISSN] 1472-0213
  • [Journal-full-title] Emergency medicine journal : EMJ
  • [ISO-abbreviation] Emerg Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2658474
  •  go-up   go-down


44. Cao Y, Wang L, Nandy D, Zhang Y, Basu A, Radisky D, Mukhopadhyay D: Neuropilin-1 upholds dedifferentiation and propagation phenotypes of renal cell carcinoma cells by activating Akt and sonic hedgehog axes. Cancer Res; 2008 Nov 1;68(21):8667-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuropilin-1 upholds dedifferentiation and propagation phenotypes of renal cell carcinoma cells by activating Akt and sonic hedgehog axes.
  • Expression of neuropilin-1 (NRP-1) has been shown in many cancer cells, but its molecular effect on tumorigenesis is largely unknown.
  • In this report, we show that in aggressive types of renal cell carcinoma (RCC), NRP-1 is expressed at a high level.
  • We show that after knockdown of NRP-1 by short hairpin RNA, RCC cells express significantly lower levels of MDM-2 and p63 proteins but higher levels of p53, and exhibit reduced migration and invasion.
  • When implanted in mice, RCC cells with a reduced NRP-1 level have a statistically significant smaller tumor-forming ability than control cells.
  • Also, NRP-1 knockdown RCC cells exhibit a more differentiated phenotype, as evidenced by the expression of epithelial-specific and kidney-specific cadherins, and the inhibition of sonic hedgehog expression participated in this effect.
  • Our study reveals that NRP-1 helps maintain an undifferentiated phenotype in cancer cells.

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 2004 Sep;131(17):4371-80 [15294868.001]
  • [Cites] PLoS One. 2007;2(11):e1161 [18000534.001]
  • [Cites] Cell. 1997 Aug 22;90(4):739-51 [9288753.001]
  • [Cites] Cell. 1997 Aug 22;90(4):753-62 [9288754.001]
  • [Cites] Cell. 1998 Mar 20;92(6):735-45 [9529250.001]
  • [Cites] Physiol Rev. 1999 Oct;79(4):1157-91 [10508232.001]
  • [Cites] Development. 1999 Nov;126(21):4895-902 [10518505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9523-8 [15983386.001]
  • [Cites] Mol Cell Biol. 2005 Sep;25(17):7441-8 [16107693.001]
  • [Cites] Development. 2006 Feb;133(3):569-78 [16396903.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):584-93 [16445911.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1099-107 [16731741.001]
  • [Cites] FASEB J. 2006 Jul;20(9):1513-5 [16754745.001]
  • [Cites] Mol Cancer Res. 2006 Oct;4(10):759-68 [17050669.001]
  • [Cites] Development. 2002 Nov;129(22):5301-12 [12399320.001]
  • [Cites] Cell. 2003 Apr 4;113(1):11-23 [12679031.001]
  • [Cites] J Biol Chem. 2006 Nov 10;281(45):33860-70 [16943197.001]
  • [Cites] J Biol Chem. 2003 Dec 5;278(49):48848-60 [14514674.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):53-67 [17222790.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):229-40 [15380514.001]
  • (PMID = 18974107.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078383-10; United States / NHLBI NIH HHS / HL / R01 HL070567-08; United States / NHLBI NIH HHS / HL / R01 HL072178-06; United States / NHLBI NIH HHS / HL / R01 HL072178; United States / NCI NIH HHS / CA / R29 CA078383; United States / NCI NIH HHS / CA / CA78383; United States / NCI NIH HHS / CA / R01 CA078383; United States / NHLBI NIH HHS / HL / R01 HL070567
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Hedgehog Proteins; 0 / SHH protein, human; 144713-63-3 / Neuropilin-1; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ NIHMS104644; NLM/ PMC3964774
  •  go-up   go-down


45. Sakamoto A, Yoshida T, Matsuura S, Tanaka K, Matsuda S, Oda Y, Hori Y, Yokomizo A, Iwamoto Y: Metastasis to the gluteus maximus muscle from renal cell carcinoma with special emphasis on MRI features. World J Surg Oncol; 2007;5:88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis to the gluteus maximus muscle from renal cell carcinoma with special emphasis on MRI features.
  • BACKGROUND: The skeletal muscle is an unusual site for metastasis from renal cell carcinoma (RCC).
  • Metastatic RCC must be differentiated from benign primary soft-tissue tumors because aggressive surgical resection is necessary.
  • CASE PRESENTATION: We present the case of a 65-year-old man with metastatic RCC in the gluteus maximus muscle (3.8 cm in diameter) found on enhanced computed tomography (CT) 6 years after nephrectomy.
  • Because the growth of the lesion was slow, benign tumor was a differential diagnosis.
  • The MRI features were unusual for most soft-tissue tumors having low-signal intensity on T1-WI and high-signal intensity on T2-WI.
  • Therefore, under a diagnosis of metastatic RCC, the lesion was resected together with the surrounding skeletal muscle.
  • The histology was confirmed to be metastatic RCC.
  • CONCLUSION: MRI features of metastatic RCC may be beneficial in differentiating it from primary soft-tissue tumor.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2000 Jun;174(6):1623-8 [10845496.001]
  • [Cites] Skeletal Radiol. 2000 Apr;29(4):187-95 [10855466.001]
  • [Cites] J Orthop Sci. 2001;6(2):189-92 [11484108.001]
  • [Cites] Acta Chir Belg. 2002 Oct;102(5):351-2 [12471771.001]
  • [Cites] J Ultrasound Med. 2005 Oct;24(10):1419-23; quiz 1424-5 [16179627.001]
  • [Cites] Eur Urol. 1991;20(2):167-9 [1752278.001]
  • [Cites] J Urol. 1996 Jul;156(1):173 [8648786.001]
  • [Cites] Tumori. 1990 Aug 31;76(4):407-9 [2399572.001]
  • [Cites] Cancer. 1973 Nov;32(5):1030-42 [4131758.001]
  • [Cites] J Urol. 1981 Jul;126(1):17-23 [7253072.001]
  • [Cites] Skeletal Radiol. 1995 May;24(4):267-70 [7644939.001]
  • [Cites] Scand J Urol Nephrol. 1993;27(1):143-4 [8493466.001]
  • [Cites] Urol Clin North Am. 1993 May;20(2):247-62 [8493748.001]
  • [Cites] Int Surg. 1990 Jul-Sep;75(3):198-202 [2242976.001]
  • (PMID = 17683570.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1976113
  •  go-up   go-down


46. Piscioli I, Donato S, Morelli L, Del Nonno F, Licci S: Renal cell carcinoma with sarcomatoid features and peritumoral sarcoid-like granulomatous reaction: report of a case and review of the literature. Int J Surg Pathol; 2008 Jul;16(3):345-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma with sarcomatoid features and peritumoral sarcoid-like granulomatous reaction: report of a case and review of the literature.
  • Granulomatous inflammation with multinucleated giant cells is observed in various infectious and noninfectious diseases.
  • It has been found in association with malignant tumors and designated sarcoid-like reaction.
  • The distinction between a tumor-related granulomatous reaction and a true sarcoidosis can be a problematic issue.
  • A case of renal cell carcinoma with sarcomatoid features (Fuhrman nuclear grade IV) with an extensive peritumoral sarcoid-like reaction and a critical review of the few cases of this association described in the literature have been reported, and the problematic clinical and pathological assessments of such lesions are discussed.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Granuloma / pathology. Kidney Neoplasms / pathology. Sarcoidosis / pathology. Sarcoma / pathology
  • [MeSH-minor] Aged. Cell Nucleus / pathology. Diagnostic Techniques, Urological. Fatal Outcome. Humans. Male


47. Nagamitsu A, Greish K, Maeda H: Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. Jpn J Clin Oncol; 2009 Nov;39(11):756-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors.
  • The purpose of this study is to evaluate the improved method of arterial infusion therapy of SMANCS (SX) with lipiodol under the angiotensin-induced hypertensive state for various difficult-to-treat solid tumors.
  • Most patients were unresectable with no other therapeutic options, recurrence after resection, or patients do not respond to common treatments.
  • This method was successfully applied to metastatic liver cancer, cholangiocarcinoma, massive renal cell carcinoma, pancreatic and other abdominal solid cancers.
  • This AT-induced hypertension resulted in remarkably enhanced tumor delivery accompanied by improved therapeutic response, and a shorter time to achieve 50% regression of tumor size with least toxicity.
  • We demonstrated clinically herein improved therapy for various advanced solid tumors with SX by elevating the tumor blood flow selectively.
  • This is the first clinical proof that modulations of vascular pathophysiology can uniquely accomplish enhanced tumor selective delivery of polymeric drugs and thus yielded better clinical outcome.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Carcinoma, Renal Cell / drug therapy. Cholangiocarcinoma / drug therapy. Drug Delivery Systems. Female. Humans. Infusions, Intravenous. Japan. Kidney Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Male. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19596662.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Maleic Anhydrides; 0 / Polystyrenes; 0 / Vasoconstrictor Agents; 0 / poly(maleic acid-styrene)neocarzinostatin; 11128-99-7 / Angiotensin II; 9014-02-2 / Zinostatin
  •  go-up   go-down


48. Stec R, Grala B, Maczewski M, Bodnar L, Szczylik C: Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease. J Exp Clin Cancer Res; 2009;28:134
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease.
  • Chromophobe renal cell carcinoma (ChRCC) is a subtype of renal cell carcinoma (RCC).
  • Eighty six percent of ChRCCs cases are diagnosed in stage 1 or 2.
  • Prognosis of ChRCC is better than in other types of RCC.
  • Five- and 10-year disease free survival (DFS) for ChRCC was 83.9% and 77.9%, respectively.
  • Expression of immunohistological markers: cytokeratins (CK), vimentin, epithelial membrane antigen (EMA), CD10 could be potentially helpful in diagnosis of different subtypes of RCC.
  • From all conventional RCC, CD 117 was detected (overexpression) in membrane of cells ChRCC.Overexpression of CD117 on cellular membranes of ChRCC could be a potential target for kinase inhibitors like: imatinib, dasatinib, nilotinib.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell. Kidney Neoplasms. Proto-Oncogene Proteins c-kit / metabolism
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Male


49. Mahmoudnejad N, Danesh A, Abdi H: Renal cell carcinoma in presacral pelvic kidney. J Pak Med Assoc; 2009 Jul;59(7):482-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma in presacral pelvic kidney.
  • Renal pelvic ectopia has been estimated to occur in 1 of 2100 to 3000 autopsies.
  • Renal cell carcinoma (RCC) is a very rare phenomenon in an ectopic kidney.
  • According to our review of literature, there are only seven reports of RCC occurrence in pelvic kidneys.
  • We describe a patient with RCC of presacral ectopic kidney who underwent radical nephrectomy at our medical center.
  • [MeSH-major] Carcinoma, Renal Cell. Kidney Neoplasms

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19579741.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


50. Gigante M, Mandic M, Wesa AK, Cavalcanti E, Dambrosio M, Mancini V, Battaglia M, Gesualdo L, Storkus WJ, Ranieri E: Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients. J Immunother; 2008 Apr;31(3):254-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients.
  • Dendritic cells (DCs) are potent antigen presenting cells and represent attractive candidates for use in novel immunotherapies for patients with renal cell carcinoma (RCC), a disease that has proven refractory to conventional treatment modalities, such as chemotherapy and radiotherapy.
  • Given the perceived need to augment antitumor type-1 immunity (TC1 and Th1) as a therapeutic end point, and the known functional plasticity of DC populations that may display heterogeneous capacity to promote T-cell responses, we sought to identify a preferred DC preparation with this capacity.
  • We compared 2 different preparations of monocyte-derived DC using interferon-alpha (IFN-alpha) (IFN-DC and alphaDC1) with classic DCs "matured" (mDCs) using interleukin-1beta/interleukin-6/tumor necrosis factor-alpha/prostaglandin E2, for their ability to promote autologous TC1 antitumor responses from RCC patients in vitro.
  • IFN-alpha-conditioned DC promoted significantly higher numbers of RCC-specific CD8+ T cells exhibiting a cytotoxic phenotype after in vitro stimulation (IVS) than cytokine cocktail-mDCs.
  • Furthermore, IVS using IFN-DCs was able to diminish regulatory-type T cells among CD4+ T-cell responder populations versus IVS using conventional mDC-based vaccines.
  • These data emphasize an important role for IFN-alpha in modulating the immunologic functions of DCs toward a polarized DC1-type capable of coordinately promoting TH1-type and TC1-type T-cell mediated immunity and supports the translational development of patient-derived IFN-alpha-conditioned DC for use in novel immunotherapies for patients with RCC, and in whom, endogenous tumor-specific TC1 effector cells may be dysfunctional, anergic, or prone to undergo apoptosis.
  • [MeSH-major] Carcinoma, Renal Cell / immunology. Dendritic Cells / immunology. Interferon-alpha / immunology. Kidney Neoplasms / immunology. Lymphocyte Activation. T-Lymphocytes, Regulatory / immunology. Th1 Cells / immunology
  • [MeSH-minor] Cell Communication. Cell Differentiation / drug effects. Cell Differentiation / immunology. Cells, Cultured. Cytokines / immunology. Cytotoxicity, Immunologic. Humans. Immunologic Memory. Immunotherapy, Active. Interferon Type I / immunology. Interferon Type I / pharmacology. Interferon-gamma / immunology. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317362.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interferon Type I; 0 / Interferon-alpha; 0 / Recombinant Proteins; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


51. Escudero JU, de Campos MR, López SC, Deltoro MF, Vidal EM: [Surgical treatment of the renal carcinoma with inferior vena cava thrombus and filter]. Arch Esp Urol; 2008 Jul-Aug;61(6):730-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of the renal carcinoma with inferior vena cava thrombus and filter].
  • [Transliterated title] Tratamiento quirúrgico de carcinoma renal con trombo y filtro en vena cava.
  • OBJECTIVE: Vascular invasion in the form of tumour thrombus appears in a significant percentage of renal neoplasias.
  • RESULTS: Although in the past it was believed tumour thrombus worsened prognosis in these patients, currently we know that surgical treatment, in selected cases, gives good results in terms of survival and disease-free time.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Neoplastic Cells, Circulating. Vena Cava Filters. Vena Cava, Inferior

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705196.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


52. D'Alterio C, Consales C, Polimeno M, Franco R, Cindolo L, Portella L, Cioffi M, Calemma R, Marra L, Claudio L, Perdonà S, Pignata S, Facchini G, Cartenì G, Longo N, Pucci L, Ottaiano A, Costantini S, Castello G, Scala S: Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer. Curr Cancer Drug Targets; 2010 Nov;10(7):772-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer.
  • CXCR4 is a chemokine receptor implicated in the metastatic process.
  • The CXCR4 ligand, CXCL12, was shown to bind also the CXCR7 receptor, a recently deorphanized chemokine receptor whose signalling pathway and function are still controversial.
  • This study was conducted to determine patients clinic-pathological factors and outcome according to the expressions of CXCR4 and CXCR7 in renal cell carcinoma (RCC).
  • CXCR4 and CXCR7 expression was evaluated in 223 RCC patients through immunohistochemistry; moreover CXCR4 and CXCR7 was detected in 49 others consecutive RCC patients trough RT- PCR.
  • CXCR4 expression was low in 42/223 RCC (18.8%), intermediate in 71/223 (31.9%) and high in 110/223 (49.3%).
  • CXCR7 expression was low in 44/223 RCC patients (19.8%), intermediate in 65/223 (29.1%) and high in 114/223 (51.1%).
  • High CXCR4 and high CXCR7 expression predicted shorter disease free survival.
  • Through RT-PCR, CXCR4 was overexpressed in 36/49 and CXCR7 in 33/49 samples correlating with symptoms at diagnosis and lymph nodes status.
  • So we can hypothesize that CXCR4 and CXCR7, singularly evaluated and in combination, are valuable prognostic factors in RCC patients.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / diagnosis. Kidney Neoplasms / metabolism. Receptors, CXCR / metabolism. Receptors, CXCR4 / metabolism
  • [MeSH-minor] Aged. Aging. Disease-Free Survival. Female. Humans. Immunohistochemistry. Kidney / metabolism. Kidney / pathology. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20578990.001).
  • [ISSN] 1873-5576
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CXCR4 protein, human; 0 / CXCR7 protein, human; 0 / RNA, Messenger; 0 / Receptors, CXCR; 0 / Receptors, CXCR4
  •  go-up   go-down


53. Karaca H, Lale A, Dikilitas M, Ozkan M, Er O: Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature. Med Oncol; 2010 Sep;27(3):1023-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature.
  • It has higher response rates and progression-free survival in patients with metastatic renal cell carcinoma (RCC) when compared with standard chemotherapy and interferon-alpha.
  • We report a case of paraneoplastic hypercalcemia, resistant to conventional treatment but recovers by sunitinib treatment as the first case in the literature, in a 33-years-old man with metastatic RCC.
  • Besides sunitinib is effective in symptom control, it is also helpful in management of paraneoplastic hypercalcemia, a life-threatening entity.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Hypercalcemia / drug therapy. Indoles / therapeutic use. Kidney Neoplasms / drug therapy. Paraneoplastic Syndromes / drug therapy. Protein Kinase Inhibitors / therapeutic use. Pyrroles / therapeutic use
  • [MeSH-minor] Adult. Combined Modality Therapy. Disease Progression. Humans. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Male. Nephrectomy. Pneumonectomy / methods

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urol Int. 2001;67(2):175-7 [11490218.001]
  • [Cites] Clin Exp Metastasis. 2003;20(8):757-66 [14713109.001]
  • [Cites] J Gen Intern Med. 2007 Jul;22(7):1042-6 [17443359.001]
  • [Cites] J Clin Oncol. 1999 Jul;17 (7):2039-43 [10561255.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):454-63 [14752067.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 9;338(1):627-38 [16153592.001]
  • [Cites] Am J Med Sci. 2006 Mar;331(3):119-23 [16538071.001]
  • [Cites] Mol Cancer Ther. 2003 May;2(5):471-8 [12748309.001]
  • [Cites] Cancer. 1993 Feb 15;71(4):1309-12 [8382106.001]
  • [Cites] Endocr Pract. 2006 Sep-Oct;12(5):535-41 [17002928.001]
  • [Cites] Semin Oncol. 1990 Apr;17(2 Suppl 5):26-33 [2185550.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1287-95 [12727920.001]
  • [Cites] Ann Surg. 1971 Nov;174(5):863-5 [5113467.001]
  • [Cites] N Engl J Med. 2005 Jan 27;352(4):373-9 [15673803.001]
  • [Cites] Urology. 1989 Mar;33(3):167-70 [2521966.001]
  • [Cites] Tumour Biol. 2005 Jul-Aug;26(4):201-6 [16006777.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):909-18 [14990647.001]
  • [Cites] Blood. 2003 May 1;101(9):3597-605 [12531805.001]
  • [Cites] Rev Urol. 2002 Fall;4(4):163-70 [16985675.001]
  • [Cites] Clin Calcium. 2006 Apr;16(4):665-69 [16582519.001]
  • [Cites] FASEB J. 2004 Feb;18(2):338-40 [14657001.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):327-37 [12538485.001]
  • [Cites] N Engl J Med. 1984 Jun 28;310(26):1718-27 [6328302.001]
  • (PMID = 19830602.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Protein Kinase Inhibitors; 0 / Pyrroles; V99T50803M / sunitinib
  •  go-up   go-down


54. Perut F, Cenni E, Unger RE, Kirkpatrick CJ, Giunti A, Baldini N: Immunogenic properties of renal cell carcinoma and the pathogenesis of osteolytic bone metastases. Int J Oncol; 2009 May;34(5):1387-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunogenic properties of renal cell carcinoma and the pathogenesis of osteolytic bone metastases.
  • The immunogenic properties of renal cell carcinoma (RCC) on bone osteolysis were investigated. mRNA expression of three proinflammatory cytokines, monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6) and interleukin-8 (IL-8), were determined in a panel of RCC lines (CRBM 1990, ACHN and Caki-1).
  • Moreover proinflammatory cytokine mRNA expression and protein levels of adhesion molecules, intercellular adhesion molecule-1 (ICAM-1) and E-selectin, on human umbilical vein endothelial cells (HUVEC) incubated with the conditioned media from RCC lines were evaluated.
  • RCC express mRNA of MCP-1, IL-6 and IL-8 that may induce a proinflammatory phenotype in endothelial cells. mRNA expression of IL-6, and IL-8 was induced on HUVEC treated with the conditioned media from RCC lines and mRNA and protein levels of ICAM-1 and E-selectin were also increased.
  • This study demonstrates the immunogenic properties of renal cell carcinoma, such as pro-inflammatory cytokine secretion and the induction of adhesion molecules (ICAM-1 and E-Sel) by endothelial cells.
  • Osteolysis in bone metastases, mediated by this pathway, may be further potentiated by the pro-angiogenic properties of RCC.
  • [MeSH-major] Bone Neoplasms / etiology. Carcinoma, Renal Cell / immunology. Inflammation Mediators / metabolism. Kidney Neoplasms / immunology. Osteolysis / etiology
  • [MeSH-minor] Cells, Cultured. Culture Media, Conditioned / pharmacology. Cytokines / genetics. Cytokines / metabolism. Cytokines / pharmacology. E-Selectin / genetics. E-Selectin / metabolism. Endothelial Cells / drug effects. Endothelial Cells / metabolism. Gene Expression Regulation / drug effects. Humans. Intercellular Adhesion Molecule-1 / genetics. Intercellular Adhesion Molecule-1 / metabolism. Models, Biological. Vascular Cell Adhesion Molecule-1 / genetics. Vascular Cell Adhesion Molecule-1 / metabolism


55. Gómez-Ferrer Lozano A, Navarro Antón JA, Sala Aznar A, Mola Arizo MJ, Polo i Peris AC: [Unilocular cystic renal carcinoma]. Actas Urol Esp; 2007 Jul-Aug;31(7):792-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unilocular cystic renal carcinoma].
  • [Transliterated title] Carcinoma quístico unilocular.
  • We report the case of unilocular cystic renal cell carcinoma and its radiological findings.
  • Cystic renal cell carcinomas are among 3 to 7% of kidney cancers and sometimes are difficult to diagnose, as it happened in this case.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17902478.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


56. Mohammed A, Shergill I, Little B: Management of metastatic renal cell carcinoma: current trends. Expert Rev Mol Diagn; 2009 Jan;9(1):75-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of metastatic renal cell carcinoma: current trends.
  • Renal cell carcinoma is one of the common malignancies of the genitourinary tract.
  • In approximately one third of patients, distant metastases are present at the time of initial diagnosis and in another third, the tumor will recur even after nephrectomy with a curative intent.
  • Renal cell carcinoma is resistant to all conventional treatment modalities of cancer, including radiotherapy and chemotherapy.
  • We review the management of patients with metastatic renal cell carcinoma in the era of the new targeted therapeutic agents.
  • [MeSH-major] Carcinoma, Renal Cell / therapy. Kidney Neoplasms / therapy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19099350.001).
  • [ISSN] 1744-8352
  • [Journal-full-title] Expert review of molecular diagnostics
  • [ISO-abbreviation] Expert Rev. Mol. Diagn.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Protein Kinase Inhibitors
  • [Number-of-references] 61
  •  go-up   go-down


57. Laco J, Celakovsky P, Kalfert D, Hornychova H, Rybnikar T, Ryska A: Tumor-to-tumor metastasis: Warthin tumor as a recipient of lung carcinoma and of renal carcinoma - Report of two cases. Pathol Res Pract; 2010 Jul 15;206(7):458-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-to-tumor metastasis: Warthin tumor as a recipient of lung carcinoma and of renal carcinoma - Report of two cases.
  • Tumor-to-tumor metastasis is an exceedingly rare event with only about 100 cases reported in the English written literature.
  • We report two cases of a 65-year-old man with duplicity of colonic and lung adenocarcinomas who presented with swelling of the left parotid gland, and of a 75-year-old man who presented with swelling of the right parotid gland.
  • Microscopical and immunohistochemical examination showed metastasis of lung carcinoma and of renal carcinoma, respectively, to Warthin tumor as the first clinical manifestation of the malignancy in the latter case.
  • [MeSH-major] Adenocarcinoma / secondary. Adenolymphoma / pathology. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Lung Neoplasms / pathology. Parotid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19625134.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


58. Mimura I, Tojo A, Kinugasa S, Uozaki H, Fujita T: Renal cell carcinoma in association with IgA nephropathy in the elderly. Am J Med Sci; 2009 Nov;338(5):431-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma in association with IgA nephropathy in the elderly.
  • IgA nephropathy can occur as a paraneoplastic syndrome of renal cell carcinoma.
  • We report 3 cases of IgA nephropathy associated with renal cell carcinoma in the elderly patients and demonstrate that infiltrating lymphocytes and plasma cells around renal cell carcinoma produce IgA that likely contributed to mesangial IgA deposition.
  • [MeSH-major] Carcinoma, Renal Cell / complications. Glomerulonephritis, IGA / complications. Kidney Neoplasms / complications

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19773639.001).
  • [ISSN] 1538-2990
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


59. Horstmann M, Merseburger AS, von der Heyde E, Serth J, Wegener G, Mengel M, Feil G, Hennenlotter J, Nagele U, Anastasiadis A, Bokemeyer C, Stenzl A, Kuczyk M: Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels. J Cancer Res Clin Oncol; 2005 Nov;131(11):715-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels.
  • The prognostic value of bFGF for surgically treated renal cell cancer (RCC) patients was evaluated by immunohistochemistry (IHC) and the tissue microarray technique (TMA).
  • Additionally, preoperative serum bFGF levels were correlated to tumour stage and the presence of metastases at initial diagnosis.
  • Serum levels of bFGF were measured by ELISA in 39 healthy volunteers, in 37 patients with benign urologic diseases and in 74 RCC patients, 26 of whom revealed lymph node or distant metastases. bFGF expression as detected by IHC was investigated in 777 tissue cores from 259 different RCC patients [median follow-up: 138 (36-240) months].
  • Eighty eight patients died from tumour progression.
  • For each patient, the TMA slides contained a tissue core from the primary tumour, its invasion front and the normal renal parenchyma. bFGF serum levels were higher in RCC patients vs healthy volunteers (P<0.01) and vs patients with benign urologic diseases (P<0.01).
  • In multivariate analysis regional LN metastases (P<0.01), the histological grading (P<0.01), and an increased bFGF expression in the invasion front (P=0.04) independently predicted the patients' clinical prognosis.
  • Not the expression of bFGF in the primary tumour but in its invasion front reflects the aggressiveness of RCC, hereby indicating a different biological potential within both areas.
  • The value of bFGF serum levels as indicators of systemic tumour dissemination remains to be determined.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Fibroblast Growth Factor 2 / metabolism. Kidney Neoplasms / metabolism. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Predictive Value of Tests. Prognosis. Protein Array Analysis. Survival Analysis

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1995 Sep-Oct;15(5B):2331-3 [8572647.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1207-25 [11181687.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4641-52 [14581333.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2C):1463-6 [10365124.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] Br J Urol. 1996 Sep;78(3):351-3 [8881940.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6D):5117-20 [11326680.001]
  • [Cites] J Urol. 2000 Jan;163(1):343-7 [10604387.001]
  • [Cites] Oncol Rep. 2001 Nov-Dec;8(6):1401-7 [11605074.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2451-8 [9815646.001]
  • [Cites] Eur Urol. 2003 Mar;43(3):309-19 [12600436.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2C):1537-40 [10365140.001]
  • [Cites] Cancer Res. 1988 Apr 15;48(8):2083-8 [3349479.001]
  • [Cites] J Urol. 2003 Mar;169(3):821-7 [12576793.001]
  • [Cites] Jpn J Cancer Res. 1995 Feb;86(2):182-6 [7730142.001]
  • [Cites] J Urol. 1994 Nov;152(5 Pt 1):1626-31 [7523715.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2002 Jan;11(1):37-42 [11753085.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2C):1557-61 [10365145.001]
  • [Cites] J Urol. 2001 Nov;166(5):1611-23 [11586189.001]
  • [Cites] Curr Opin Oncol. 2000 May;12(3):260-4 [10841199.001]
  • [Cites] N Engl J Med. 2001 Dec 6;345(23 ):1711-2 [11759660.001]
  • [Cites] CMAJ. 2001 Mar 6;164(5):662-70 [11258215.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2C):1541-3 [10365141.001]
  • [Cites] Am J Pathol. 1994 Aug;145(2):365-74 [8053494.001]
  • [Cites] Endocr Relat Cancer. 2000 Sep;7(3):165-97 [11021964.001]
  • [Cites] Recent Prog Horm Res. 2000;55:15-35; discussion 35-6 [11036931.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):735-43 [11159211.001]
  • [Cites] Genome Biol. 2001;2(3):REVIEWS3005 [11276432.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(17):2199-203 [11677107.001]
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1B):869-73 [10216508.001]
  • (PMID = 16080018.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


60. Cuda SP, Brand TC, Thibault GP, Sutherland RS: Collecting duct carcinoma arising from multicystic dysplastic kidney disease. J Pediatr Urol; 2006 Oct;2(5):500-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collecting duct carcinoma arising from multicystic dysplastic kidney disease.
  • Malignancy arising from a multicystic dysplastic kidney (MCDK) is rare.
  • Most reports are of Wilms' tumor and clear-cell renal cell carcinoma arising from a previously unrecognized MCDK.
  • To our knowledge, no reports have described collecting duct carcinoma arising from MCDK.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18947667.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


61. Ulutin HC, Aksu G, Fayda M, Kuzhan O, Tahmaz L, Beyzadeoglu M: The value of postoperative radiotherapy in renal cell carcinoma: a single-institution experience. Tumori; 2006 May-Jun;92(3):202-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of postoperative radiotherapy in renal cell carcinoma: a single-institution experience.
  • AIM: To evaluate the efficacy of postoperative irradiation in renal cell carcinoma.
  • PATIENTS AND METHODS: Forty patients with localized renal cell carcinoma admitted to our hospital between 1986 and 1999 were evaluated.
  • Histopathological diagnosis was renal cell carcinoma in all of the patients.
  • N+ disease was present in 3 patients (7%).
  • Stage I and II disease was present in 25 patients (63%) and stage III and IV disease in 15 patients (37%).
  • Two patients (5%) had T1a disease, 11 patients (27%) had T1b, 15 patients (38%) had T2, 11 patients (27%) had T3a and 1 (3%) patient had T3b.
  • In the radiotherapy group, renal bed and regional lymphatic fields were irradiated with daily fractions of 180-200 cGy/fraction to a total dose of 46-50 Gy, using parallel opposing fields.
  • The 5-year disease-free survival rates were 66% in the radiotherapy group and 16% in the no treatment group, with a significant difference in both univariate and multivariate analyses (P = 0.045 and P = 0.0007, respectively).
  • Stage III and IV disease, tumor size 27 cm, presence of distant metastasis and lactate dehydrogenase level > 450 U/L were found to be adverse prognostic factors for overall survival in both univariate and multivariate analyses.
  • Analyzing the factors affecting disease-free survival, absence of postoperative radiotherapy and tumor size > or = 7 cm were found to be adverse prognostic factors in univariate and multivariate analyses.
  • CONCLUSION: Multi-institutional prospective randomized trials using modern radiotherapy techniques such as conformal radiotherapy and intensity-modulated radiotherapy are necessary to evaluate the real role of radiotherapy and its effect on survival in renal cell carcinoma, especially in selected patients with a high risk of local or regional failure.
  • [MeSH-major] Carcinoma, Renal Cell / radiotherapy. Kidney Neoplasms / radiotherapy. Nephrectomy
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Disease-Free Survival. Dose Fractionation. Female. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Radiotherapy, Conformal. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16869236.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


62. Sakurai K, Fukazawa H, Arihara Z, Yoshida K: Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume. Tohoku J Exp Med; 2010 Sep;222(1):39-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sunitinib, a tyrosine kinase inhibitor, has been approved for the treatment of cancers, such as advanced renal cell carcinoma (RCC).
  • On the other hand, sunitinib treatment is known to induce thyroid dysfunction in a substantial proportion of patients treated for advanced RCC; in fact, hypothyroidism is a frequent complication.
  • Here, we report a patient with RCC who developed transient overt thyrotoxicosis followed by hypothyroidism due to sunitinib treatment.
  • A 58-year-old woman, who had been treated with chronic thyroiditis, was diagnosed as having left RCC with bone metastasis to the rib.
  • The patient underwent resection of the left kidney and the bone metastasis lesion.

  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20814176.001).
  • [ISSN] 1349-3329
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Indoles; 0 / Protein Kinase Inhibitors; 0 / Pyrroles; 0 / sunitinib
  •  go-up   go-down


63. Zieger K: High throughput molecular diagnostics in bladder cancer - on the brink of clinical utility. Mol Oncol; 2008 Apr;1(4):384-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High throughput molecular diagnostics in bladder cancer - on the brink of clinical utility.
  • An enormous body of high-throughput genome-wide data, in particular gene expression data, has been gathered from roughly all human cancer forms in the past 10 years.
  • This has widely increased our understanding of the cancer disease and its molecular changes and pathways, with a large contribution from studies of cancer cell lines and functional genomics.
  • The huge variability of molecular changes and poor availability of samples have hampered progress in the field of epithelial cancer (carcinoma).
  • However, independent validation of molecular profiles across high-throughput platforms, methods, laboratories and cancer populations has recently been successfully performed for several carcinomas, including bladder cancer.
  • Application of advanced bioinformatics to identify interrelated pathways has revealed common signatures predictive of molecular subgroups, improving histopathological diagnosis, and ultimately outcome prediction.
  • With breast cancer leading the field, colorectal, bladder and renal cell carcinomas well on their way, and many others soon to join, the era of clinical applications of high-throughput molecular methods in cancer lies closely ahead.
  • This review illustrates in detail the perspectives for the management of bladder cancer.
  • [MeSH-major] Molecular Diagnostic Techniques / methods. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor. Computational Biology / methods. Gene Expression Profiling. Humans. Prognosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2001 Jun;158(6):1955-9 [11395371.001]
  • [Cites] Eur Urol. 2004 Mar;45(3):292-6 [15036673.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3410-21 [15161696.001]
  • [Cites] Lung Cancer. 2007 May;56(2):175-84 [17258348.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Carcinogenesis. 2004 Aug;25(8):1345-57 [15001537.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2540-8 [15481058.001]
  • [Cites] Cancer Sci. 2007 Jan;98(1):113-7 [17116130.001]
  • [Cites] Bioinformatics. 2007 Jun 15;23(12):1550-2 [17384422.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):498-507 [17255271.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):864-70 [15829956.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):389-98 [16495705.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):4040-8 [15173019.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jun;46(6):532-42 [17330261.001]
  • [Cites] Scand J Urol Nephrol Suppl. 1987;104:127-32 [3481460.001]
  • [Cites] Lancet. 2003 Nov 1;362(9394):1439-44 [14602436.001]
  • [Cites] Mol Diagn Ther. 2006;10(5):271-80 [17022690.001]
  • [Cites] Oncogene. 2006 Apr 27;25(18):2685-96 [16532037.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6418-23 [12438227.001]
  • [Cites] Bioinformatics. 2005 Jun 1;21(11):2766-72 [15814560.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3800-6 [15173088.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4407-14 [17671123.001]
  • [Cites] Eur Urol. 2005 Apr;47(4):456-62 [15774241.001]
  • [Cites] BMC Genomics. 2006 Apr 27;7:96 [16643655.001]
  • [Cites] Oncogene. 2007 Mar 1;26(10):1507-16 [16936776.001]
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5552-64 [17158541.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):517-25 [17290060.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4415-29 [15958626.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):107-16 [16491070.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):7012-22 [16203795.001]
  • [Cites] Genes Chromosomes Cancer. 2007 May;46(5):427-39 [17285574.001]
  • [Cites] PLoS Med. 2006 Jan;3(1):e13 [16318415.001]
  • [Cites] Mol Oncol. 2008 Apr;1(4):384-94 [19383312.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7709-19 [16278391.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):90-6 [12469123.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):505-16 [12875971.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jul;46(7):661-9 [17420988.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):560-9 [16899776.001]
  • [Cites] Lancet. 2005 Feb 5-11;365(9458):488-92 [15705458.001]
  • [Cites] Lab Invest. 2005 Apr;85(4):532-49 [15778693.001]
  • [Cites] Int J Cancer. 2006 Dec 1;119(11):2642-50 [16991122.001]
  • [Cites] BMC Genomics. 2006 May 26;7:127 [16729877.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4021-5 [10945601.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2063-8 [17119029.001]
  • [Cites] Gastroenterology. 2007 Feb;132(2):645-53 [17258723.001]
  • [Cites] BMC Bioinformatics. 2005 Nov 04;6:265 [16271137.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4029-36 [15930337.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):34-45 [15665277.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2625-36 [15814643.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6379-85 [17085649.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] J Mol Diagn. 2006 Feb;8(1):68-75 [16436636.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13(4):1017-31 [17158752.001]
  • [Cites] Curr Opin Oncol. 2006 Jul;18(4):374-80 [16721134.001]
  • [Cites] Nat Rev Cancer. 2007 Jul;7(7):545-53 [17585334.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8861-8 [14695203.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3545-51 [17575217.001]
  • [Cites] Breast Cancer Res. 2006;8(2):R23 [16626501.001]
  • [Cites] Clin Genitourin Cancer. 2006 Dec;5(3):187-9 [17239271.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4044-55 [15930339.001]
  • [Cites] BMC Bioinformatics. 2006 Jul 20;7:354 [16857057.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2284-93 [15136595.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1915-9 [16721812.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5723-6 [14522891.001]
  • [Cites] Curr Opin Urol. 2003 Sep;13(5):357-62 [12917511.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1491-502 [11290567.001]
  • [Cites] Eur Urol. 2007 Jan;51(1):161-6; discussion 166-7 [16828965.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):361-73 [16352616.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 15;98(4):262-72 [16478745.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 17;99(2):147-57 [17227998.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2216-22 [12727842.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Oct 15;170(2):133-9 [17011984.001]
  • [Cites] Carcinogenesis. 2006 Apr;27(4):740-7 [16338952.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):778-89 [16432078.001]
  • [Cites] Hum Mol Genet. 2003 Oct 15;12 Spec No 2:R153-7 [12928487.001]
  • (PMID = 19383312.001).
  • [ISSN] 1878-0261
  • [Journal-full-title] Molecular oncology
  • [ISO-abbreviation] Mol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 46
  •  go-up   go-down


64. Zhang L, Huang H, Wu K, Wang M, Wu B: Impact of BTG2 expression on proliferation and invasion of gastric cancer cells in vitro. Mol Biol Rep; 2010 Jul;37(6):2579-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of BTG2 expression on proliferation and invasion of gastric cancer cells in vitro.
  • BTG2 (B cell translocation gene 2) is downregulated in several human tumors and has been known as a tumor suppressor in carcinogenesis of thymus, prostate, kidney, and liver.
  • However, little is known about the role BTG2 plays in gastric adenocarcinoma.
  • In the present study, we intended to investigate the influence of BTG2 on the growth, proliferation, apoptosis, invasion and cell cycle of the gastric cancer cell lines SGC7901 and MKN45.
  • BTG2 cDNA was insected into a constitutive vector pcDNA3.1 followed by transfection in gastric cancer cell line MKN45 and SGC7901 by using liposome.
  • The apoptosis and cell cycles of these transfectants were analyzed by using flow cytometric assay.
  • The growth and proliferation were analyzed by cell growth curves and colony-forming assay, respectively.
  • The invasion of these clones was analyzed by using cell migration assay.
  • MKN-BTG2 (MKN45 with stable transfection of BTG2 gene) and SGC-BTG2 (SGC7901 with stable transfection of BTG2 gene) grew slower than their control groups, respectively.
  • The cell counts of MKN-BTG2 in the fourth, fifth, sixth and seventh days were significantly fewer than those of control groups (P < 0.05).
  • Those of SGC-BTG2 in the fourth fifth, sixth and seventh days were significantly fewer than those of control groups too (P < 0.05).
  • Cell cycle analysis showed that proportions of MKN-BTG2 and SGC-BTG2 cells in G0-G1 and S were different significantly with those of their control groups, respectively (P < 0.05).
  • The apoptosis rate of MKN-BTG2 was significantly higher than those of control groups (P < 0.05).
  • Results of colony-forming assay showed that the colon formation rates of MKN-BTG2 and SGC-BTG2 were lower than those of their control groups (P < 0.05).
  • The results of cell migration assay showed that the cell migration rates of MKN-BTG2 and SGC-BTG2 were not significantly different with those of their control groups (P > 0.05).
  • BTG2 can restrain the growth and proliferation of gastric cancer cells powerfully.
  • It can reduce some malignant phenotype of these tumor cells.
  • But it could not impact the ability of invasion of gastric cancer cells, so could not restrain the metastasis of gastric cancer.
  • In gastric cancer, BTG2 could be thought as a tumor-inhibiting gene in some distance, so the gene could be a potential target of gene therapy.
  • [MeSH-major] Cell Movement / genetics. Immediate-Early Proteins / genetics. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Apoptosis / genetics. Blotting, Western. Cell Cycle / genetics. Cell Line, Tumor. Cell Proliferation. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Neoplasm Invasiveness. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Tumor Stem Cell Assay

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1997 Mar;11(3):370-5 [9067576.001]
  • [Cites] Gene. 2002 Jan 9;282(1-2):207-14 [11814693.001]
  • [Cites] Oncogene. 2002 Oct 3;21(44):6772-78 [12360398.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7075-82 [16849553.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(5):1797-815 [10669755.001]
  • [Cites] J Biol Chem. 1991 Aug 5;266(22):14511-8 [1713584.001]
  • [Cites] Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2004 Apr;21(2):110-5 [15079790.001]
  • [Cites] J Cancer Res Clin Oncol. 1995;121(5):279-84 [7768965.001]
  • [Cites] Oncogene. 1999 Dec 9;18(52):7432-41 [10602502.001]
  • [Cites] FASEB J. 2007 Jul;21(9):2215-25 [17371797.001]
  • [Cites] J Cell Physiol. 2001 May;187(2):155-65 [11267995.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Jul;132(7):417-26 [16456675.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):609-15 [17234770.001]
  • [Cites] World J Gastroenterol. 2006 Jan 21;12(3):354-62 [16489633.001]
  • [Cites] Oncogene Res. 1987 Sep-Oct;1(4):343-55 [3130602.001]
  • [Cites] Surg Clin North Am. 2000 Apr;80(2):659-82; discussions 683-6 [10836011.001]
  • [Cites] Asian J Androl. 2005 Dec;7(4):375-80 [16281084.001]
  • [Cites] Cell Signal. 2009 May;21(5):801-9 [19263516.001]
  • [Cites] Genomics. 2000 Sep 15;68(3):253-63 [10995567.001]
  • [Cites] FEBS Lett. 2001 May 25;497(2-3):67-72 [11377414.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1632-8 [14996721.001]
  • [Cites] Carcinogenesis. 2001 Aug;22(8):1271-9 [11470758.001]
  • [Cites] Exp Cell Res. 2004 Sep 10;299(1):159-70 [15302583.001]
  • (PMID = 19728149.001).
  • [ISSN] 1573-4978
  • [Journal-full-title] Molecular biology reports
  • [ISO-abbreviation] Mol. Biol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Immediate-Early Proteins; 0 / Tumor Suppressor Proteins; 141490-22-4 / BTG2 protein, human
  •  go-up   go-down


65. Leisegang M, Turqueti-Neves A, Engels B, Blankenstein T, Schendel DJ, Uckert W, Noessner E: T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy. Clin Cancer Res; 2010 Apr 15;16(8):2333-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
  • PURPOSE: Adoptive therapy with genetically engineered T cells carrying redirected antigen specificity is a new option for the treatment of cancer.
  • This approach is not yet available for metastatic renal cell carcinoma (RCC), due to the scarcity of therapeutically useful reagents.
  • We analyzed tumor-infiltrating lymphocytes (TIL) from RCC to identify T-cell specificities with shared tumor-specific recognition to develop T-cell receptor (TCR)-engineered T lymphocytes for adoptive therapy of RCC.
  • EXPERIMENTAL DESIGN: We established a T-cell clone from TIL that recognized a human leukocyte antigen (HLA)-A2-restricted tumor antigen.
  • A TCR-expressing indicator line (B3Z-TCR53) was established to screen for antigen prevalence in RCC, other malignancies, and normal cell counterparts.
  • RESULTS: TCR53-engineered PBL recapitulated the specificity of the TIL and showed tumor-specific HLA-A2-restricted effector activities (IFN-gamma, tumor necrosis factor-alpha, interleukin-2, macrophage inflammatory protein-1beta, cytotoxicity).
  • PBL-TCR53 of healthy donors and RCC patients exhibited similar transduction efficiency, expansion, and polyfunctional profile.
  • Using B3Z-TCR53 cells, 130 tumor and normal cells were screened and shared TCR53 peptide: MHC expression was found in >60% of RCC and 25% of tumor lines of other histology, whereas normal tissue cells were not recognized.
  • CONCLUSIONS: To date, TCR53 is the only TCR with shared HLA-A2-restricted recognition of RCC.
  • It fulfills the criteria for utilization in TCR gene therapy and advances T cell-based immunotherapy to patients with RCC and other malignancies expressing the TCR ligand.
  • [MeSH-major] Carcinoma, Renal Cell / therapy. Immunotherapy, Adoptive. Kidney Neoplasms / therapy. Lymphocytes, Tumor-Infiltrating / immunology. Receptors, Antigen, T-Cell, alpha-beta / genetics. T-Lymphocytes / transplantation
  • [MeSH-minor] Cells, Cultured. Cytotoxicity, Immunologic / immunology. Flow Cytometry. HLA-A2 Antigen / genetics. HLA-A2 Antigen / immunology. Humans. Kidney / cytology. Kidney / metabolism. T-Cell Antigen Receptor Specificity

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20371691.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA-A2 Antigen; 0 / Receptors, Antigen, T-Cell, alpha-beta
  •  go-up   go-down


66. Yockman JW, Kim WJ, Chang CW, Kim SW: Non-viral delivery of interleukin-2 and soluble Flk-1 inhibits metastatic and primary tumor growth in renal cell carcinoma. Gene Ther; 2007 Oct;14(19):1399-405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-viral delivery of interleukin-2 and soluble Flk-1 inhibits metastatic and primary tumor growth in renal cell carcinoma.
  • Treatments for renal cell carcinoma, while promising, are still limited by toxicity and cost.
  • In the hopes of finding a novel compound or combination, we developed a plasmid containing the genes for interleukin-2 (IL-2) and soluble vascular endothelial growth factor receptor 2 (msFlk1).
  • Subcutaneous tumor growth was significantly inhibited in the p2CMVIL2/msFlk1 group when delivered locally by the non-viral water soluble polymer, WSLP and exhibited a 50% increase in survival over glucose and single-agent controls.
  • Furthermore, tumor-infiltrating lymphocytes expressing CD45RO and CD68 were increased within the tumor microenvironment upon p2CMVIL2/msFlk1 treatment.
  • Our work clearly demonstrates that non-viral delivery of p2CMVIL2/msFlk1 can inhibit RENCA growth in a synergistic manner and may represent a new treatment for renal carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / therapy. Genetic Therapy / methods. Immunotherapy / methods. Interleukin-2 / genetics. Kidney Neoplasms / therapy. Vascular Endothelial Growth Factor Receptor-2 / genetics

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17653245.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA107070
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Drug Carriers; 0 / Interleukin-2; 0 / Lipids; 0 / PEI-g-PEG-RGD; 0 / Peptides, Cyclic; 0 / poly(ethylenimine)-co-(N-(2-aminoethyl) ethyleneimin)-co-N-(N-cholesteryloxycarbonyl-(2-aminoethyl)ethylenimine); 30IQX730WE / Polyethylene Glycols; 9002-98-6 / Polyethyleneimine; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


67. Rankin EB, Tomaszewski JE, Haase VH: Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res; 2006 Mar 1;66(5):2576-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor.
  • Inactivation of the von Hippel-Lindau tumor suppressor, pVHL, is associated with both hereditary and sporadic renal cysts and renal cell carcinoma, which are commonly thought to arise from the renal proximal tubule. pVHL regulates the protein stability of hypoxia-inducible factor (HIF)-alpha subunits and loss of pVHL function leads to HIF stabilization.
  • The role of HIF in the development of VHL-associated renal lesions remains to be determined.
  • To investigate the functional consequences of pVHL inactivation and the role of HIF signaling in renal epithelial cells, we used the phosphoenolpyruvate carboxykinase (PEPCK) promoter to generate transgenic mice in which Cre-recombinase is expressed in the renal proximal tubule and in hepatocytes.
  • We found that conditional inactivation of VHL in PEPCK-Cre mutants resulted in renal cyst development that was associated with increased erythropoietin levels and polycythemia.
  • Increased expression of the HIF target gene erythropoietin was limited to the liver, whereas expression of carbonic anhydrase 9 and multidrug resistance gene 1 was up-regulated in the renal cortex of mutant mice.
  • Inactivation of the HIF-alpha binding partner, arylhydrocarbon receptor nuclear translocator (Arnt), but not Hif-1alpha, suppressed the development of renal cysts.
  • Here, we present the first mouse model of VHL-associated renal disease that will provide a basis for further genetic studies to define the molecular events that are required for the progression of VHL-associated renal cysts to clear cell renal cell carcinoma.

  • MedlinePlus Health Information. consumer health - Kidney Cysts.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem J. 1979 Sep 1;181(3):525-32 [391220.001]
  • [Cites] Am J Anat. 1983 Nov;168(3):345-62 [6196964.001]
  • [Cites] Nature. 1987 Dec 10-16;330(6148):576-8 [3683574.001]
  • [Cites] Hum Pathol. 1988 Sep;19(9):1072-9 [3417291.001]
  • [Cites] Mod Pathol. 1991 Mar;4(2):210-4 [2047384.001]
  • [Cites] Nucleic Acids Res. 1991 Aug 11;19(15):4293 [1870982.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8725-9 [1924331.001]
  • [Cites] FASEB J. 1992 Dec;6(15):3330-7 [1281456.001]
  • [Cites] Science. 1993 May 28;260(5112):1317-20 [8493574.001]
  • [Cites] Kidney Int. 1993 Nov;44(5):1149-62 [8264149.001]
  • [Cites] J Biol Chem. 1994 Feb 25;269(8):5619-28 [8119898.001]
  • [Cites] J Clin Invest. 1994 May;93(5):2175-88 [7910173.001]
  • [Cites] Nat Genet. 1994 May;7(1):85-90 [7915601.001]
  • [Cites] Development. 1995 May;121(5):1487-96 [7789278.001]
  • [Cites] J Urol. 1995 Dec;154(6):2010-4; discussion 2014-5 [7500446.001]
  • [Cites] Nat Med. 1995 Aug;1(8):822-6 [7585187.001]
  • [Cites] N Engl J Med. 1996 Sep 19;335(12):865-75 [8778606.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9067-72 [8799155.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10589-94 [8855222.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10595-9 [8855223.001]
  • [Cites] Annu Rev Biochem. 1997;66:581-611 [9242918.001]
  • [Cites] Nature. 1999 May 20;399(6733):271-5 [10353251.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1059-64 [15709172.001]
  • [Cites] Mol Cell Biol. 2005 Apr;25(8):3163-72 [15798202.001]
  • [Cites] Mol Cell Biol. 2005 Jul;25(13):5675-86 [15964822.001]
  • [Cites] Exp Physiol. 2004 Jul;89(4):435-44 [15131073.001]
  • [Cites] Histopathology. 2000 May;36(5):457-65 [10792488.001]
  • [Cites] Kidney Int. 2000 Aug;58(2):647-57 [10916088.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4010-5 [10945599.001]
  • [Cites] Oncogene. 2000 Nov 16;19(48):5435-43 [11114720.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1583-8 [11171994.001]
  • [Cites] Curr Opin Cell Biol. 2001 Apr;13(2):167-71 [11248550.001]
  • [Cites] Science. 2001 Apr 20;292(5516):464-8 [11292862.001]
  • [Cites] Science. 2001 Apr 20;292(5516):468-72 [11292861.001]
  • [Cites] Blood. 2002 May 15;99(10):3562-5 [11986208.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3387-94 [12067980.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):237-46 [12086860.001]
  • [Cites] J Am Soc Nephrol. 2002 Jul;13(7):1721-32 [12089367.001]
  • [Cites] Cancer Cell. 2002 Jun;1(5):459-68 [12124175.001]
  • [Cites] FASEB J. 2002 Aug;16(10):1151-62 [12153983.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):673-82 [12209156.001]
  • [Cites] FASEB J. 2003 Feb;17(2):271-3 [12490539.001]
  • [Cites] J Biol Chem. 2003 Mar 28;278(13):11032-40 [12538644.001]
  • [Cites] Lancet. 2003 Jun 14;361(9374):2059-67 [12814730.001]
  • [Cites] Urol Clin North Am. 2003 Aug;30(3):437-54, vii [12953747.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Feb;36(2):189-204 [14643885.001]
  • [Cites] Mol Cancer Res. 2004 Feb;2(2):89-95 [14985465.001]
  • [Cites] PLoS Biol. 2003 Dec;1(3):E83 [14691554.001]
  • [Cites] J Biol Chem. 2004 Apr 16;279(16):16326-31 [14764592.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12436-41 [10535940.001]
  • [Cites] Oncogene. 2004 Jul 22;23(33):5624-31 [15184875.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):223-8 [15380513.001]
  • [Cites] J Am Soc Nephrol. 2004 Oct;15(10):2569-78 [15466261.001]
  • (PMID = 16510575.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK050306; United States / NCI NIH HHS / CA / R01 CA100787; United States / NIDDK NIH HHS / DK / P30-DK50306; United States / NCI NIH HHS / CA / R01-CA100787
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arnt protein, mouse; 0 / Hif1a protein, mouse; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Recombinases; 138391-32-9 / Aryl Hydrocarbon Receptor Nuclear Translocator; EC 4.1.1.31 / Phosphoenolpyruvate Carboxylase; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  • [Other-IDs] NLM/ NIHMS306646; NLM/ PMC3514875
  •  go-up   go-down


68. Sokolova O, Bozko PM, Naumann M: Helicobacter pylori suppresses glycogen synthase kinase 3beta to promote beta-catenin activity. J Biol Chem; 2008 Oct 24;283(43):29367-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The human pathogen Helicobacter pylori influences cell adhesion, proliferation, and apoptosis and is involved in gastric adenocarcinoma formation.
  • In our study we analyzed the impact of H. pylori infection on the regulation of beta-catenin, which plays a central role in both cell adhesion and tumorigenesis.
  • Infection of Madin-Darby canine kidney cells with H. pylori led to suppression of Ser/Thr phosphorylation and ubiquitin-dependent degradation of beta-catenin and to up-regulation of lymphoid enhancer-binding factor/T cell factor (LEF/TCF)-dependent transcription.
  • We conclude that glycogen synthase kinase 3beta activity exerts an important role in beta-catenin regulation and LEF/TCF transactivation in H. pylori-infected Madin-Darby canine kidney cells.
  • [MeSH-minor] Animals. Cell Line. Cyclin D1 / biosynthesis. Dogs. Helicobacter Infections / diagnosis. Helicobacter Infections / metabolism. Lymphoid Enhancer-Binding Factor 1 / metabolism. Models, Biological. Phosphorylation. Proto-Oncogene Proteins c-akt / metabolism. RNA, Small Interfering / metabolism. Transcriptional Activation. Up-Regulation

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2008 Feb 15;122(4):823-31 [17960618.001]
  • [Cites] FEMS Microbiol Rev. 2006 Jan;30(1):131-56 [16438683.001]
  • [Cites] J Cell Sci. 2008 Jun 1;121(11):1793-802 [18460581.001]
  • [Cites] Gut. 2006 Jun;55(6):775-81 [16322107.001]
  • [Cites] J Clin Pathol. 2006 Dec;59(12):1261-6 [16679349.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4617-26 [17237808.001]
  • [Cites] Exp Cell Res. 2007 Oct 1;313(16):3459-71 [17692843.001]
  • [Cites] Adv Cancer Res. 2000;77:1-24 [10549354.001]
  • [Cites] Genes Cells. 1999 Dec;4(12):757-67 [10620020.001]
  • [Cites] Science. 2000 Mar 3;287(5458):1606-9 [10733430.001]
  • [Cites] Ann N Y Acad Sci. 2000 Jun;910:21-33; discussion 33-5 [10911903.001]
  • [Cites] Pathol Int. 2000 Oct;50(10):767-77 [11107048.001]
  • [Cites] Cell. 2001 May 4;105(3):391-402 [11348595.001]
  • [Cites] Oncology. 2001;60(4):339-45 [11408802.001]
  • [Cites] Int J Oncol. 2001 Sep;19(3):533-6 [11494032.001]
  • [Cites] J Biol Chem. 2001 Oct 5;276(40):37436-42 [11495916.001]
  • [Cites] Mol Cell Biol. 2002 Jan;22(2):578-86 [11756553.001]
  • [Cites] EMBO Rep. 2002 Jan;3(1):63-8 [11751573.001]
  • [Cites] FASEB J. 2002 Mar;16(3):417-9 [11790728.001]
  • [Cites] Cell. 2002 Mar 22;108(6):837-47 [11955436.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Apr;16 Suppl 2:145-57 [11966535.001]
  • [Cites] Dev Dyn. 2002 May;224(1):18-29 [11984870.001]
  • [Cites] J Cell Sci. 2002 Jul 1;115(Pt 13):2771-80 [12077367.001]
  • [Cites] Neoplasma. 2002;49(2):95-100 [12088113.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jul 19;295(3):695-701 [12099696.001]
  • [Cites] Cancer Biol Ther. 2002 May-Jun;1(3):226-31 [12432268.001]
  • [Cites] Jpn J Cancer Res. 2002 Nov;93(11):1213-20 [12460462.001]
  • [Cites] Mol Pathol. 2003 Feb;56(1):19-24 [12560457.001]
  • [Cites] Int J Surg Pathol. 2003 Jan;11(1):1-9 [12598910.001]
  • [Cites] J Cell Sci. 2003 Apr 1;116(Pt 7):1175-86 [12615961.001]
  • [Cites] J Cell Biol. 2003 Apr 28;161(2):249-55 [12719469.001]
  • [Cites] Trends Microbiol. 2004 Jan;12(1):29-36 [14700549.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):537-60 [14713266.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Apr 16;316(4):1065-72 [15044093.001]
  • [Cites] Pathology. 2004 Apr;36(2):120-8 [15203747.001]
  • [Cites] Gene. 2004 Oct 27;341:1-17 [15474284.001]
  • [Cites] J Cell Biol. 2004 Oct 25;167(2):339-49 [15492040.001]
  • [Cites] Mol Microbiol. 1994 Apr;12(2):307-19 [8057855.001]
  • [Cites] Nature. 1995 Dec 21-28;378(6559):785-9 [8524413.001]
  • [Cites] Science. 1996 May 17;272(5264):1023-6 [8638126.001]
  • [Cites] Curr Biol. 1996 Dec 1;6(12):1664-8 [8994831.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3797-804 [9233789.001]
  • [Cites] J Biol Chem. 1997 Oct 3;272(40):24735-8 [9312064.001]
  • [Cites] Oncogene. 1999 Jan 28;18(4):849-54 [10023660.001]
  • [Cites] Curr Biol. 1999 Feb 25;9(4):207-10 [10074433.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5522-7 [10318916.001]
  • [Cites] Cell Microbiol. 2004 Dec;6(12):1153-66 [15527495.001]
  • [Cites] Biochem J. 2005 Jan 15;385(Pt 2):399-408 [15456405.001]
  • [Cites] J Surg Oncol. 2005 Jun 1;90(3):114-33; discussion 133 [15895459.001]
  • [Cites] Cells Tissues Organs. 2005;179(1-2):56-65 [15942193.001]
  • [Cites] World J Gastroenterol. 2005 Jul 28;11(28):4400-3 [16038041.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10646-51 [16027366.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):499-508 [16107313.001]
  • [Cites] Int J Med Microbiol. 2005 Sep;295(5):335-41 [16173500.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Sep;24(3):337-45 [16270519.001]
  • [Cites] J Exp Med. 2005 Nov 7;202(9):1235-47 [16275761.001]
  • [Cites] Hum Pathol. 2005 Dec;36(12):1294-301 [16311123.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):261-76 [16354697.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):379-87 [18199531.001]
  • (PMID = 18772141.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lymphoid Enhancer-Binding Factor 1; 0 / RNA, Small Interfering; 0 / beta Catenin; 136601-57-5 / Cyclin D1; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / glycogen synthase kinase 3 beta; EC 2.7.11.26 / Glycogen Synthase Kinase 3
  • [Other-IDs] NLM/ PMC2662023
  •  go-up   go-down


69. Ambrose M, Ryan A, O'Sullivan GC, Dunne C, Barry OP: Induction of apoptosis in renal cell carcinoma by reactive oxygen species: involvement of extracellular signal-regulated kinase 1/2, p38delta/gamma, cyclooxygenase-2 down-regulation, and translocation of apoptosis-inducing factor. Mol Pharmacol; 2006 Jun;69(6):1879-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of apoptosis in renal cell carcinoma by reactive oxygen species: involvement of extracellular signal-regulated kinase 1/2, p38delta/gamma, cyclooxygenase-2 down-regulation, and translocation of apoptosis-inducing factor.
  • Renal cell carcinoma (RCC) is the most common malignancy of the kidney.
  • Unfortunately, RCCs are highly refractory to conventional chemotherapy, radiation therapy, and even immunotherapy.
  • Thus, novel therapeutic targets need to be sought for the successful treatment of RCCs.
  • We now report that 6-anilino-5,8-quinolinequinone (LY83583), an inhibitor of cyclic GMP production, induced growth arrest and apoptosis of the RCC cell line 786-0.
  • It did not prove deleterious to normal renal epithelial cells, an important aspect of chemotherapy.
  • LY83583 induced a time- and dose-dependent increase in RCC apoptosis through dephosphorylation of mitogen-activated protein kinase kinase 1/2 and its downstream extracellular signal-regulated kinases (ERK) 1 and -2.
  • Cell death was associated with a decrease and increase in Bcl-x(L) and Bax expression, respectively, as well as release of cytochrome c and translocation of apoptosis-inducing factor.
  • In conclusion, our results suggest that LY83583 may represent a novel therapeutic agent for the treatment of RCC, which remains highly refractory to antineoplastic agents.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Apoptosis. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Reactive Oxygen Species / metabolism
  • [MeSH-minor] Apoptosis Inducing Factor / metabolism. Apoptosis Regulatory Proteins / genetics. Cell Line, Tumor. Cyclooxygenase 2 / metabolism. Down-Regulation. Gene Expression / drug effects. Humans. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 12 / metabolism. Mitogen-Activated Protein Kinase 13 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Protein Transport / drug effects


70. Yamada T, McElderry HT, Doppalapudi H, Murakami Y, Yoshida Y, Yoshida N, Okada T, Tsuboi N, Inden Y, Murohara T, Epstein AE, Plumb VJ, Singh SP, Kay GN: Idiopathic ventricular arrhythmias originating from the aortic root prevalence, electrocardiographic and electrophysiologic characteristics, and results of radiofrequency catheter ablation. J Am Coll Cardiol; 2008 Jul 8;52(2):139-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We studied 265 patients with idiopathic VAs with an inferior QRS-axis morphology.
  • The site of the origin was the left coronary cusp (LCC) in 24 (54.5%), the right coronary cusp (RCC) in 14 (31.8%), the noncoronary cusp (NCC) in 1 (2.3%), and at the junction between the LCC and RCC (L-RCC) in 5 (11.4%) cases.
  • The maximum amplitude of the R-wave in the inferior leads was significantly greater with an LCC than with an RCC origin (p < 0.05).
  • The ratio of the R-wave amplitude in leads II and III was significantly greater with an LCC than with an RCC origin (p < 0.01) and was significantly smaller in the NCC than in the other sites (p < 0.0001).
  • The ventricular deflection in the His bundle electrogram was significantly later relative to the surface QRS with an LCC or L-RCC origin than with an RCC or NCC origin (p < 0.0001).
  • CONCLUSIONS: Idiopathic VAs are more common in the LCC than in the RCC and rarely arise from the NCC.

  • MedlinePlus Health Information. consumer health - Arrhythmia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18598894.001).
  • [ISSN] 1558-3597
  • [Journal-full-title] Journal of the American College of Cardiology
  • [ISO-abbreviation] J. Am. Coll. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Gilbert SM, Murphy AM, Katz AE, Goluboff ET, Sawczuk IS, Olsson CA, Benson MC, McKiernan JM: Reevaluation of TNM staging of renal cortical tumors: recurrence and survival for T1N0M0 and T3aN0M0 tumors are equivalent. Urology; 2006 Aug;68(2):287-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reevaluation of TNM staging of renal cortical tumors: recurrence and survival for T1N0M0 and T3aN0M0 tumors are equivalent.
  • OBJECTIVES: The current TNM staging system for renal cortical tumors (RCTs) differentiates between tumors confined to the kidney (T1, T2) and tumors that extend through the renal capsule and invade into the perinephric fat (T3a).
  • We examined the relative survival rates of patients with T1 and T3a tumors to determine the accuracy of the current TNM staging classification.
  • METHODS: We analyzed the Columbia University Surgical Urological Oncology Database for all patients with clinically localized Stage T1, T2, and T3a RCTs treated surgically from 1988 to 2004.
  • Because the T3a classification is not limited by size, we compared T3a tumors with T1 tumors alone and tumors confined within the renal capsule (Stage T1 and T2 tumors combined).
  • After the exclusion criteria were applied, 131 patients with T1N0M0, 19 patients with T2N0M0, and 82 patients with T3aN0M0 conventional renal cell carcinoma were eligible for analysis.
  • The median tumor diameter was 3.2, 3.8, and 5.0 cm for Stage T1, T1 and T2 combined, and T3a lesions, respectively.
  • The estimated 5-year disease-free survival was 95.2% and 90.6% for T1 and T3a RCTs, respectively (P = 0.922).
  • CONCLUSIONS: Patients with Stage T3a tumors experienced similar outcomes as patients with tumors confined to the renal capsule.
  • [MeSH-major] Carcinoma, Renal Cell / mortality. Carcinoma, Renal Cell / pathology. Kidney Cortex. Kidney Neoplasms / mortality. Kidney Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16904438.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Cao Y, Paner GP, Perry KT, Flanigan RC, Campbell SC, Picken MM: Renal neoplasms in younger adults: analysis of 112 tumors from a single institution according to the new 2004 World Health Organization classification and 2002 American Joint Committee on Cancer Staging System. Arch Pathol Lab Med; 2005 Apr;129(4):487-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal neoplasms in younger adults: analysis of 112 tumors from a single institution according to the new 2004 World Health Organization classification and 2002 American Joint Committee on Cancer Staging System.
  • CONTEXT: Adult renal neoplasms have a predilection for older patients and are clinically and morphologically distinct from renal neoplasms found in pediatric age groups.
  • Relatively rare tumors occur in younger adults (18-45 years of age).
  • Whether these renal tumors are morphologically and clinically distinct from those of older adults has been the subject of controversy.
  • Recent modification of the World Health Organization histologic classification and the American Joint Committee on Cancer staging system of adult renal tumors further highlighted the need for case analysis in this age group.
  • OBJECTIVE: To analyze renal tumors in younger adults based on a large surgical series from a single institution.
  • DESIGN: Of 780 renal mass nephrectomy (partial, total, or radical) specimens that were available for evaluation and had been obtained between 1986 and 2004 at Loyola University Medical Center, 112 specimens were from patients between 18 and 45 years of age.
  • The tumors were reevaluated according to the 2004 World Health Organization classification and the 2002 American Joint Committee on Cancer staging system.
  • RESULTS: The likelihood of clear cell renal cell carcinoma was significantly reduced from 65% in older adults to 53% in younger adults (18-45 years, P = .04).
  • The majority (64%) of clear cell renal cell carcinoma in younger adults was low stage, T1a.
  • Seventeen percent of these tumors had multilocular cystic features involving more than 50% of the tumor volume (55%-85%).
  • In contrast, the miscellaneous tumor category showed a remarkable increase, from 4% in older adults to 26% in younger adults (P < .001).
  • The youngest patient group (18-35 years) had a higher incidence of miscellaneous tumors, 37%.
  • Clear cell and chromophobe renal cell carcinoma occurred more frequently in younger male adults than in female adults (2:1 and 8:1, respectively).
  • CONCLUSIONS: Renal neoplasms are more heterogeneous in younger adults and have a different distribution pattern compared with that in older adults.
  • Malignant and benign renal neoplasms tend to have a contrasting sex distribution in younger adults.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15794671.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Yang Y, Valera VA, Padilla-Nash HM, Sourbier C, Vocke CD, Vira MA, Abu-Asab MS, Bratslavsky G, Tsokos M, Merino MJ, Pinto PA, Srinivasan R, Ried T, Neckers L, Linehan WM: UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet Cytogenet; 2010 Jan 1;196(1):45-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.
  • Energy deregulation and abnormalities of tumor cell metabolism are critical issues in understanding cancer.
  • Hereditary leiomyomatosis renal cell carcinoma (HLRCC) is an aggressive form of RCC characterized by germline mutation of the Krebs cycle enzyme fumarate hydratase (FH), and one known to be highly metastatic and unusually lethal.
  • There is considerable utility in establishing preclinical cell and xenograft models for study of disorders of energy metabolism, as well as in development of new therapeutic approaches targeting of tricarboxylic acid (TCA) cycle enzyme-deficient human cancers.
  • Here we describe a new immortalized cell line, UOK 262, derived from a patient having aggressive HLRCC-associated recurring kidney cancer.
  • UOK 262 cells have an isochromosome 1q recurring chromosome abnormality, i(1)(q10), and exhibit compromised oxidative phosphorylation and in vitro dependence on anaerobic glycolysis consistent with the clinical manifestation of HLRCC.
  • The cells also display glucose-dependent growth, an elevated rate of lactate efflux, and overexpression of the glucose transporter GLUT1 and of lactate dehydrogenase A (LDHA).
  • Our findings indicate that the severe compromise of oxidative phosphorylation and rapid glycolytic flux in UOK 262 are an essential feature of this TCA cycle enzyme-deficient form of kidney cancer.
  • This tumor model is the embodiment of the Warburg effect.
  • UOK 262 provides a unique in vitro and in vivo preclinical model for studying the bioenergetics of the Warburg effect in human cancer.


74. Matsukawa Y, Hattori R, Komatsu T, Yoshino Y, Ono Y, Gotoh M: [Two cases of bilateral renal cell carcinoma in patients with Von Hipple-Lindau disease]. Hinyokika Kiyo; 2007 Jan;53(1):61-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of bilateral renal cell carcinoma in patients with Von Hipple-Lindau disease].
  • Von Hipple-Lindau (VHL) disease is a rare familial cancer syndrome that is dominantly inherited and pre-disposes affected individuals to developing various tumors, including hemangioblastoma of the retina and central nervous system, and multicentric renal cell carcinoma.
  • We report two cases of VHL disease with bilateral renal cell carcinoma.
  • Case 1: A 53-year-old woman was referred to our hospital because of bilateral kidney tumor incidentally found.
  • We performed left laparoscopic radical nephrectomy and laparoscopic nephrectomy, ex vivo excision and reconstruction, and autotransplantation for the right kidney.
  • Case 2: A 43-year-old woman was referred to our hospital because of left kidney tumor incidentally found.
  • Because the suspectious lesion in the right kidney was very small, we decided to follow it up with no treatment.
  • We performed laparoscopic nephrectomy, ex vivo excision and reconstruction, and autotransplantation for left kidney.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. von Hippel-Lindau Disease / complications


75. Yumura Y, Yamashita Y, Senga Y, Jinza S, Goro A: [Two cases of renal cell carcinoma with diabetes mellitus that was healed after nephrectomy]. Hinyokika Kiyo; 2007 May;53(5):301-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of renal cell carcinoma with diabetes mellitus that was healed after nephrectomy].
  • Two cases of renal cell carcinoma presenting with uncontrolled diabetes mellitus are reported.
  • A 61 and 64-year-old women with hyperglycemia were incidentally found to have a right renal tumor.
  • Immunohistological study revealed the tumor cells positive in one case and negative in the other case for interleukin (IL) 6.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Diabetes Complications / physiopathology. Kidney Neoplasms / surgery


76. Davis ID, Liu Z, Saunders W, Lee FT, Spirkoska V, Hopkins W, Smyth FE, Chong G, Papenfuss AT, Chappell B, Poon A, Saunder TH, Hoffman EW, Old LJ, Scott AM: A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. Cancer Immun; 2007;7:14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma.
  • We studied the effects of adding daily low-dose subcutaneous IL-2 to cG250 for treatment of clear cell renal cell carcinoma (RCC).
  • The primary endpoints of the trial were toxicity and immunological effects (human anti-chimeric antibodies [HACA], ADCC, natural killer [NK] and lymphokine-activated killer cell [LAK] activity); secondary endpoints were cG250 biodistribution and pharmacokinetics (PK) and tumour response rates.
  • Eligible patients had unresectable metastatic or locally advanced clear cell RCC with measurable or evaluable disease.
  • No HACA was detected. (131)I-labeled cG250 showed excellent targeting of tumour deposits. (131)I cG250 PK: T(1/2)alpha 20.16 +/- 6.59 h, T(1/2)beta 126.21 +/- 34.04 h, CL 39.67 +/- 23.06 mL/h, Cmax 5.12 +/- 0.86 microg/mL, V(1) 3.88 +/- 1.05 L.
  • A trend for increased percentage of circulating CD3-/CD16+CD56+ NK cells was observed.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, Neoplasm / immunology. Carbonic Anhydrases / immunology. Carcinoma, Renal Cell / immunology. Carcinoma, Renal Cell / therapy. Interleukin-2 / therapeutic use. Kidney Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antibody-Dependent Cell Cytotoxicity. Female. Humans. Killer Cells, Lymphokine-Activated / immunology. Male. Middle Aged. Pilot Projects

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2004 Jun;171(6 Pt 1):2461-6 [15126876.001]
  • [Cites] J Nucl Med. 2004 Aug;45(8):1412-21 [15299069.001]
  • [Cites] Int J Cancer. 1986 Oct 15;38(4):489-94 [2428759.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):738-50 [8478666.001]
  • [Cites] Int J Cancer. 1994 Feb 15;56(4):609-14 [7509324.001]
  • [Cites] Biometrics. 1996 Sep;52(3):992-1001 [8805764.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1996 May;19(3):184-91 [8811493.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1529-37 [9193349.001]
  • [Cites] Cancer Immunol Immunother. 1998 Aug;46(6):318-26 [9756416.001]
  • [Cites] Clin Cancer Res. 1996 Apr;2(4):669-77 [9816217.001]
  • [Cites] Clin Cancer Res. 1998 Nov;4(11):2729-39 [9829736.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):133-41 [15625368.001]
  • [Cites] Cochrane Database Syst Rev. 2005;(1):CD001425 [15674877.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3714-21 [15897568.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6540-8 [16170161.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7178s-7186s [16203819.001]
  • [Cites] Biomarkers. 2005 Nov;10 Suppl 1:S83-6 [16298916.001]
  • [Cites] J Urol. 2006 Jan;175(1):57-62 [16406869.001]
  • [Cites] Cancer Biother Radiopharm. 2006 Jun;21(3):263-8 [16918303.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Lancet Oncol. 2007 Apr;8(4):304-10 [17395103.001]
  • [Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]
  • [Cites] Cancer Immun. 2007;7:13 [17705349.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3268s-3274s [10541374.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2530-40 [10561319.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2859-67 [10561363.001]
  • [Cites] Br J Cancer. 1999 Oct;81(4):741-6 [10574265.001]
  • [Cites] J Urol. 2000 Feb;163(2):408-17 [10647643.001]
  • [Cites] J Urol. 2000 Apr;163(4):1090-5; quiz 1295 [10737472.001]
  • [Cites] Cancer Immunol Immunother. 2002 May;51(3):171-7 [11941456.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):802-11 [12576453.001]
  • [Cites] Folia Biol (Praha). 2003;49(2):74-7 [12779016.001]
  • [Cites] Urol Clin North Am. 2003 Aug;30(3):623-31 [12953760.001]
  • [Cites] Br J Cancer. 2004 Mar 8;90(5):985-90 [14997194.001]
  • (PMID = 17705350.001).
  • [ISSN] 1424-9634
  • [Journal-full-title] Cancer immunity
  • [ISO-abbreviation] Cancer Immun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / G250 monoclonal antibody; 0 / Interleukin-2; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  • [Other-IDs] NLM/ PMC2935743
  •  go-up   go-down


77. Kim KH, Han EM, Lee ES, Park HS, Kim I, Kim YS: Epstein-Barr virus infection in sarcomatoid renal cell carcinoma tissues. BJU Int; 2005 Sep;96(4):547-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus infection in sarcomatoid renal cell carcinoma tissues.
  • OBJECTIVE: To determine whether Epstein-Barr virus (EBV) infection is related to renal cell carcinoma (RCC) tissues.
  • MATERIALS AND METHODS: We investigated EBV infection and its genotypes in 73 cases of different types of RCC and 18 of non-neoplastic kidney.
  • The immunophenotype and EBV status of the EBV-infected cells were examined by double-labelling of EBER-ISH and/or immunohistochemistry for lymphoid cell markers, EBV proteins, and CD21.
  • RESULTS: EBER-ISH signals were detected in five of 73 RCC tissues (6.8%), but in none of 18 non-neoplastic kidneys.
  • Interestingly, EBER-ISH was positive only in five of the 10 sarcomatoid RCCs, and of these, four also showed amplification of EBNA-1.
  • EBV was located exclusively in the tumour-infiltrating B lymphocytes of sarcomatoid RCCs.
  • A few EBV-infected B cells expressed BZLF1 (an EBV immediate-early gene product) while none expressed EBNA-2 or latent membrane protein 1.
  • This indicates that the B cells are of EBV latency type I, often replicating EBV.
  • EBV infection did not affect the survival rates of patients with sarcomatoid RCC (P = 0.635, Kaplan-Meier analysis, log-rank test).
  • CONCLUSION: EBV is present only in tumour-infiltrating B lymphocytes of sarcomatoid RCCs.
  • The present study suggests that sarcomatoid RCC modulates a function of EBV-specific T cells controlling EBV replication, or stimulates differentiation of memory B cells into plasma cells.
  • [MeSH-major] Carcinoma, Renal Cell / virology. Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / genetics. Kidney Neoplasms / virology. Mixed Tumor, Malignant / virology. RNA, Viral / analysis
  • [MeSH-minor] Adult. Aged. Antigens, Viral / genetics. B-Lymphocytes / virology. Biomarkers / analysis. Epstein-Barr Virus Nuclear Antigens / genetics. Female. Genotype. Humans. Immunohistochemistry / methods. In Situ Hybridization. Lymphocytes, Tumor-Infiltrating / virology. Male. Middle Aged. Polymerase Chain Reaction / methods. Receptors, Complement 3d / analysis. Sarcoma / immunology. Sarcoma / virology. Virus Latency

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] BJU Int. 2006 Jan;97(1):197-8 [16336358.001]
  • (PMID = 16104908.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Biomarkers; 0 / EBNA-3C, epstein-barr virus; 0 / EBV-encoded nuclear antigen 1; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / RNA, Viral; 0 / Receptors, Complement 3d
  •  go-up   go-down


78. Goelden U, Pfoertner S, Hansen W, Toepfer T, von Knobloch R, Hofmann R, Buer J, Schrader AJ: Expression and functional influence of cellular retinoic acid-binding protein II in renal cell carcinoma. Urol Int; 2005;75(3):269-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and functional influence of cellular retinoic acid-binding protein II in renal cell carcinoma.
  • INTRODUCTION: Retinoic acid (RA) and its derivates possess antiproliferative and tumor-suppressive abilities and are successfully used in the treatment of various malignancies.
  • However, in metastatic renal cell carcinoma (RCC), its application did not meet first expectations.
  • As the exact mechanisms of RA action and especially the role of the cellular retinoic acid-binding proteins (CRABP) still remain unclear, we studied the expression of CRABP-II and its potential influence on RA response in RCC.
  • MATERIALS AND METHODS: We used the real-time RT-PCR methodology to investigate CRABP-II expression in 12 RCC samples and corresponding normal kidney tissue.
  • Moreover, CRABP-II was cloned and overexpressed in CAKI-2 RCC cells.
  • CRABP-II (un)transfected CAKI-2 cells were stimulated with all-trans RA (ATRA) and 9-cis RA, and their antiproliferative effects were evaluated using 3H-thymidine-proliferation assays.
  • RESULTS: Using RPS9 and RPLP0 to normalize its expression, the median tumor/kidney ratio for CRABP-II expression was 0.16 and 0.12, respectively.
  • Using proliferation assays, CRABP-II overexpressing CAKI-2 cells did not exhibit a significant change in RA sensitivity, but appeared to be less sensitive toward RA-stimulation compared to CAKI-2 cells expressing naturally low levels of CRABP-II (maximum difference, 59% at 3 microM ATRA).
  • CONCLUSIONS: We were able to demonstrate a downregulation of CRABP-II expression in primary RCC tumor samples compared to the corresponding normal kidney tissue.
  • However, CRABP-II overexpression in CAKI-2 RCC cells did not significantly influence RA associated antiproliferative actions.
  • Further experiments are necessary to define the exact role of CRABP-II and its downregulation in RCC including its influence and dependence on other molecules involved in RA signalling and metabolism.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Gene Expression Regulation, Neoplastic. Kidney Neoplasms / genetics. RNA, Messenger / genetics. Receptors, Retinoic Acid / genetics
  • [MeSH-minor] Aged. Cell Line, Tumor. Cell Proliferation. Female. Genetic Markers. Humans. In Vitro Techniques. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16215318.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / RNA, Messenger; 0 / Receptors, Retinoic Acid; 0 / retinoic acid binding protein II, cellular
  •  go-up   go-down


79. Shvarts O, Janzen N, Lam JS, Leppert JT, Caliliw R, Figlin RA, Belldegrun AS, Zeng G: RENCA/carbonic anhydrase-IX: a murine model of a carbonic anhydrase-IX-expressing renal cell carcinoma. Urology; 2006 Nov;68(5):1132-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RENCA/carbonic anhydrase-IX: a murine model of a carbonic anhydrase-IX-expressing renal cell carcinoma.
  • OBJECTIVES: Carbonic anhydrase-IX (CA-IX) is a cell surface tumor-associated antigen expressed by most clear cell renal cell carcinomas (RCCs).
  • The specificity and the prognostic value of CA-IX provide impetus to create a mouse model of CA-IX-expressing RCC for testing CA-IX-targeted therapies against RCC.
  • METHODS: A retrovirus encoding the human CA-IX gene was used to transduce the murine RCC line, RENCA.
  • In the heterotopic model, subcutaneous injection of 500,000 and 50,000 cells led to tumor formation at 2 to 2.5 weeks after injection, with similar growth kinetics between the two cell lines at either cell number.
  • In the orthotopic model, autopsy revealed a CA-IX-expressing renal tumor, as well as CA-IX-expressing metastases to the lungs, liver, contralateral kidney, intestines, and lymph nodes.
  • In all the above models, the RENCA/CA-IX tumors retained expression of CA-IX, as demonstrated by immunohistochemistry staining.
  • CONCLUSIONS: RENCA/CA-IX is the first tumor model that manifests in immunocompetent Balb/c mice and stably expresses a defined kidney cancer-associated antigen.
  • It maintains antigen expression, forms metastases, and produces reliable tumor growth kinetics equivalent to that of its parental cell line.
  • [MeSH-major] Carbonic Anhydrases / biosynthesis. Carcinoma, Renal Cell / enzymology. Disease Models, Animal. Kidney Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17095063.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 4.2.1.1 / Carbonic Anhydrases; EC 4.2.1.1. / carbonic anhydrase IX, mouse
  •  go-up   go-down


80. Shaheen PE, Bukowski RM: Emerging drugs for renal cell carcinoma. Expert Opin Emerg Drugs; 2005 Nov;10(4):773-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging drugs for renal cell carcinoma.
  • Renal cell carcinoma (RCC) still represents a therapeutic challenge when patients have advanced or metastatic disease.
  • Understanding the genetic abnormalities related to the development of RCC (e.g., VHL gene abnormalities) and identifying molecular targets (e.g., epidermal growth factor, vascular endothelial growth factor and carbonic anhydrase IX) are playing a major role in the emergence of these novel agents for the treatment of this malignancy.
  • The use of oral drugs to treat various malignancies including RCC seems to be the new paradigm of the future.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Drugs, Investigational / therapeutic use. Kidney Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16262562.001).
  • [ISSN] 1744-7623
  • [Journal-full-title] Expert opinion on emerging drugs
  • [ISO-abbreviation] Expert Opin Emerg Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Investigational
  • [Number-of-references] 197
  •  go-up   go-down


81. Hasegawa Y, Mita K, Matsubara A, Ohdan H: Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient. Int J Clin Oncol; 2009 Oct;14(5):465-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient.
  • We report a case of metastatic renal cell carcinoma in the native kidney of a renal transplant recipient.
  • The patient was a 57-year-old man in whom a tumor in the native kidney and bone metastasis were found incidentally on imaging, 10 years after cadaveric renal transplantation.
  • Subsequent administration of zoledronic acid and sorafenib stabilized the disease for 18 months after nephrectomy.
  • This is the first reported case of sorafenib administration to a renal transplant recipient with metastatic renal cell carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Carcinoma, Renal Cell / drug therapy. Immunosuppressive Agents / therapeutic use. Kidney Neoplasms / therapy. Kidney Transplantation

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Oncologist. 2007 Apr;12(4):426-37 [17470685.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3150-7 [12915606.001]
  • [Cites] Transplantation. 1998 Aug 27;66(4):471-6 [9734490.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):962-9 [12942563.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Kidney Int. 2003 Mar;63(3):1130-6 [12631097.001]
  • [Cites] J Hepatol. 2003 Nov;39(5):875-8 [14568274.001]
  • [Cites] J Urol. 1994 Sep;152(3):943-5 [8051761.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):251-7 [15593084.001]
  • [Cites] J Urol. 1997 Jul;158(1):42-4 [9186319.001]
  • [Cites] Eur Urol. 2007 Jun;51(6):1502-10 [17408850.001]
  • [Cites] Br J Urol. 1995 May;75(5):572-7 [7613790.001]
  • [Cites] BJU Int. 2006 Aug;98(2):298-302 [16879668.001]
  • [Cites] Eur Urol. 1982;8(6):340-2 [6183119.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jan 1;34(1):251-66 [12118559.001]
  • [Cites] Urologe A. 1997 Mar;36(2):126-9 [9199039.001]
  • [Cites] Urology. 2007 Mar;69(3):462-4 [17382145.001]
  • (PMID = 19856059.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 0 / Immunosuppressive Agents; 0 / Interferon-alpha; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 6XC1PAD3KF / zoledronic acid; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


82. Ogiso S, Maeno A, Nagahama K, Nakamura K, Okuno H: [Small intestinal metastases from renal cell carcinoma: a case report and literature review]. Hinyokika Kiyo; 2005 Jan;51(1):13-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small intestinal metastases from renal cell carcinoma: a case report and literature review].
  • We report a case of small intestinal metastasis from renal cell carcinoma (RCC) in a 57-year-old female.
  • The patient had undergone partial nephrectomy for a right RCC (pT1aN0M0) in June 1997.
  • We removed the mass surgically, and the histological features confirmed the diagnosis as metastatic RCC.
  • Metastasis of RCC in the small bowel is a rare entity clinically.
  • To our knowledge, this is only the 20th case of small intestinal metastasis from RCC reported in the Japanese and English literature.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Ileal Neoplasms / secondary. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15732334.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 21
  •  go-up   go-down


83. Berger A, Brandina R, Atalla MA, Herati AS, Kamoi K, Aron M, Haber GP, Stein RJ, Desai MM, Kavoussi LR, Gill IS: Laparoscopic radical nephrectomy for renal cell carcinoma: oncological outcomes at 10 years or more. J Urol; 2009 Nov;182(5):2172-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic radical nephrectomy for renal cell carcinoma: oncological outcomes at 10 years or more.
  • PURPOSE: We present oncological outcomes at a followup of 10 years or greater after laparoscopic radical nephrectomy for cancer.
  • MATERIALS AND METHODS: Between February 1994 and March 1999 a total of 73 laparoscopic radical nephrectomies were performed by 2 surgeons for pathologically confirmed renal cell carcinoma.
  • Mean tumor size on computerized tomography was 5 cm (range 1.7 to 13).
  • Pathological stage was pT1a in 41% of cases, pT1b in 30%, pT2 in 15%, pT3a in 10%, pT3b in 3% and pT4 in 1%.
  • High grade tumors (Fuhrman 3 or greater) were present in 18 cases (28%).
  • Actual 10-year overall, cancer specific and recurrence-free survival rates were 65%, 92% and 86%, respectively.
  • Overall, cancer specific and recurrence-free survival rates at 12 years were 35%, 78% and 77%, respectively.
  • At a mean of 67 months 10 patients (14%) had metastatic disease, of whom 8 (11%) died.
  • CONCLUSIONS: Long-term oncological outcomes after laparoscopic radical nephrectomy for renal cell carcinoma are excellent and appear comparable to those of open surgery.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Laparoscopy. Nephrectomy / methods

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2009 Nov;182(5):2176 [19758630.001]
  • (PMID = 19758651.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Chen YJ, Liao HF, Tsai TH, Wang SY, Shiao MS: Caffeic acid phenethyl ester preferentially sensitizes CT26 colorectal adenocarcinoma to ionizing radiation without affecting bone marrow radioresponse. Int J Radiat Oncol Biol Phys; 2005 Nov 15;63(4):1252-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caffeic acid phenethyl ester preferentially sensitizes CT26 colorectal adenocarcinoma to ionizing radiation without affecting bone marrow radioresponse.
  • METHODS AND MATERIALS: The effects of CAPE on GSH level, GSH metabolism enzyme activities, NF-kappaB activity, and radiosensitivity in mouse CT26 colorectal adenocarcinoma cells were determined.
  • BALB/c mouse with CT26 cells implantation was used as a syngeneic in vivo model for evaluation of treatment and toxicity end points.
  • RESULTS: CAPE entered CT26 cells rapidly and depleted intracellular GSH in CT26 cells, but not in bone marrow cells.
  • Pretreatment with nontoxic doses of CAPE significantly enhanced cell killing by ionizing radiation (IR) with sensitizer enhancement ratios up to 2.2.
  • Pretreatment of CT26 cells with N-acetyl-L-cysteine reversed the GSH depletion activity and partially blocked the radiosensitizing effect of CAPE.
  • CAPE treatment in CT26 cells increased glutathione peroxidase, decreased glutathione reductase, and did not affect glutathione S-transferase or gamma-glutamyl transpeptidase activity.
  • In vivo study revealed that pretreatment with CAPE before IR resulted in greater inhibition of tumor growth and prolongation of survival in comparison with IR alone.
  • Pretreatment with CAPE neither affected body weights nor produced hepatic, renal, or hematopoietic toxicity.
  • CONCLUSIONS: CAPE sensitizes CT26 colorectal adenocarcinoma to IR, which may be via depleting GSH and inhibiting NF-kappaB activity, without toxicity to bone marrow, liver, and kidney.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Bone Marrow / radiation effects. Caffeic Acids / pharmacology. Colorectal Neoplasms / radiotherapy. Phenylethyl Alcohol / analogs & derivatives. Radiation-Sensitizing Agents / pharmacology
  • [MeSH-minor] Animals. Cell Cycle / drug effects. DNA Repair / drug effects. Drug Evaluation, Preclinical / methods. Glutathione / metabolism. Glutathione Peroxidase / metabolism. Mice. Mice, Inbred BALB C. NF-kappa B / metabolism. gamma-Glutamyltransferase / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 2-PHENYLETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253780.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caffeic Acids; 0 / NF-kappa B; 0 / Radiation-Sensitizing Agents; EC 1.11.1.9 / Glutathione Peroxidase; EC 2.3.2.2 / gamma-Glutamyltransferase; G960R9S5SK / caffeic acid phenethyl ester; GAN16C9B8O / Glutathione; ML9LGA7468 / Phenylethyl Alcohol
  •  go-up   go-down


85. Ingold B, Wild PJ, Nocito A, Amin MB, Storz M, Heppner FL, Moch H: Renal cell carcinoma marker reliably discriminates central nervous system haemangioblastoma from brain metastases of renal cell carcinoma. Histopathology; 2008 May;52(6):674-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma marker reliably discriminates central nervous system haemangioblastoma from brain metastases of renal cell carcinoma.
  • AIMS: The distinction between central nervous system (CNS) metastases of clear cell renal cell carcinoma (RCC) and CNS haemangioblastoma still poses a challenge to the pathologist.
  • Since both entities occur in von Hippel-Lindau disease, this aggravates the issue.
  • The antibody renal cell carcinoma marker (RCC-ma) has been suggested to identify primary RCCs specifically, but its value for diagnosing metastases of RCC is controversial.
  • The aim was to assess two distinct clones of the RCC-ma for their potential to: (i) identify primary RCCs and (ii) differentiate between CNS metastases of clear cell RCC and CNS haemangioblastomas.
  • METHODS AND RESULTS: Using tissue microarrays, 77% (n = 363; PN-15) and 66% (n = 355; 66.4C2) of clear cell RCCs, and 93% (PN-15) and 74% (66.4C2) of papillary RCCs (n = 46) were immunopositive for RCC-ma, whereas none of the investigated chromophobe RCCs (n = 22) or any of the oncocytomas (n = 15) showed immunoreactivity.
  • Importantly, 50.9% of CNS metastases of clear cell RCCs (n = 55) exhibited RCC-ma expression, whereas all CNS haemangioblastomas (71) were negative.
  • CONCLUSIONS: Both RCC-ma clones, despite some variation in their sensitivity to detect clear cell and papillary RCCs, are of value in differentiating subtypes of primary RCC and are excellent markers for discriminating clear cell lesions in the brain.
  • [MeSH-major] Antibodies, Monoclonal. Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / secondary. Hemangioblastoma / diagnosis. Kidney Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Central Nervous System Neoplasms / pathology. Humans. Neprilysin / immunology. Tissue Array Analysis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18393979.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


86. Pahernik S, Cudovic D, Roos F, Melchior SW, Thüroff JW: Bilateral synchronous sporadic renal cell carcinoma: surgical management, oncological and functional outcomes. BJU Int; 2007 Jul;100(1):26-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral synchronous sporadic renal cell carcinoma: surgical management, oncological and functional outcomes.
  • OBJECTIVE: To analyse the functional and oncological outcomes of surgical treatment of bilateral synchronous sporadic renal cell carcinoma (RCC).
  • PATIENTS AND METHODS: Between 1969 and 2006, 57 patients with bilateral synchronous sporadic RCC were identified from our kidney database.
  • The mean (range) follow-up was 4.8 (0.1-23.8) years; 28 patients (49%) had radical nephrectomy (RN) and contralateral nephron-sparing surgery (NSS), and 22 (39%) had bilateral NSS.
  • The oncological outcome and long-term renal function were analysed.
  • RESULTS: After excluding four patients (7%) with bilateral benign renal tumours, six (11%) with metastatic bilateral RCC and three (5%) who had bilateral RN, the cancer-specific outcome was analysed.
  • For 44 patients with bilateral RCC who had surgery with intent to cure and avoid dialysis, 13 (30%) had stage pT1a, 10 (23%) pT1b, nine (17%) pT2 and 12 (27%) pT3 disease.
  • At 5 and 10 years, the cancer-specific survival rates were 86% and 75%, and the local recurrence-free survival rates were 87% and 80%.
  • The median serum creatinine level at the latest follow-up was 1.18 mg/dL in patients after bilateral NSS and 1.40 mg/dL after unilateral NSS and contralateral RN (P < 0.05).
  • CONCLUSIONS: These long-term data support the concept that NSS, whenever possible bilateral, is the treatment of choice for bilateral synchronous sporadic RCC.
  • NSS provides adequate local tumour control and cancer-specific survival.
  • Preservation of renal function is more efficient with bilateral NSS than with unilateral NSS and contralateral RN.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Neoplasms, Multiple Primary / surgery. Nephrectomy / methods

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17552949.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


87. Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, Savaraj N: Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des; 2008;14(11):1049-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arginine deprivation as a targeted therapy for cancer.
  • Certain cancers may be auxotrophic for a particular amino acid, and amino acid deprivation is one method to treat these tumors.
  • Arginine deprivation is a novel approach to target tumors which lack argininosuccinate synthetase (ASS) expression.
  • Tumors which usually do not express ASS include melanoma, hepatocellular carcinoma, some mesotheliomas and some renal cell cancers.
  • Citrulline can be recycled back to arginine in normal cells which express ASS, whereas ASS(-) tumor cells cannot.
  • A pegylated form of ADI (ADI-PEG20) has been formulated and has shown in vitro and in vivo activity against melanoma and hepatocellular carcinoma.
  • ADI-PEG20 induces apoptosis in melanoma cell lines.
  • However, arginine deprivation can also induce ASS expression in certain melanoma cell lines which can lead to in vitro drug resistance.
  • Phase I and II clinical trials with ADI-PEG20 have been conducted in patients with melanoma and hepatocellular carcinoma, and antitumor activity has been demonstrated in both cancers.

  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1982 May 10;257(9):5061-7 [6279658.001]
  • [Cites] Biochem J. 1983 Nov 15;216(2):281-5 [6661196.001]
  • [Cites] J Biochem. 1985 Nov;98(5):1395-403 [4086486.001]
  • [Cites] Arch Biochem Biophys. 1987 Jul;256(1):343-53 [3038025.001]
  • [Cites] Mol Endocrinol. 1988 May;2(5):444-51 [2843756.001]
  • [Cites] J Biol Chem. 1988 Nov 5;263(31):16388-94 [3182797.001]
  • [Cites] Cancer Res. 1990 Jan 15;50(2):345-9 [2403840.001]
  • [Cites] Mol Cell Biol. 1991 Apr;11(4):1935-43 [2005889.001]
  • [Cites] Cancer Res. 1991 Jun 1;51(11):2932-9 [1903327.001]
  • [Cites] Int J Cancer. 1992 May 8;51(2):244-9 [1568792.001]
  • [Cites] Melanoma Res. 1992 Sep;2(3):191-6 [1450673.001]
  • [Cites] Arch Biochem Biophys. 1993 Mar;301(2):237-43 [8460937.001]
  • [Cites] Jpn J Cancer Res. 1993 Nov;84(11):1195-200 [8276724.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Oct 4;215(1):148-53 [7575582.001]
  • [Cites] Jpn J Cancer Res. 1995 Sep;86(9):840-6 [7591961.001]
  • [Cites] FEBS Lett. 1996 Dec 16;399(3):310-2 [8985169.001]
  • [Cites] Hepatology. 1997 Apr;25(4):964-9 [9096605.001]
  • [Cites] Am J Physiol. 1998 Jul;275(1 Pt 1):E79-86 [9688877.001]
  • [Cites] Crit Rev Oncol Hematol. 1998 Aug;28(2):97-113 [9768345.001]
  • [Cites] Biochem J. 1998 Nov 15;336 ( Pt 1):1-17 [9806879.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Jul 22;261(1):10-4 [10405315.001]
  • [Cites] Adv Exp Med Biol. 1999;457:621-9 [10500842.001]
  • [Cites] J Biol Chem. 2005 May 13;280(19):18717-27 [15772076.001]
  • [Cites] Semin Cancer Biol. 2005 Aug;15(4):247-53 [15886013.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14238-43 [16176982.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7660-8 [16234528.001]
  • [Cites] Curr Opin Cell Biol. 2005 Dec;17(6):596-603 [16226444.001]
  • [Cites] Cancer Lett. 2006 Jan 8;231(1):30-5 [16356828.001]
  • [Cites] Am J Clin Nutr. 2006 Feb;83(2):508S-512S [16470022.001]
  • [Cites] Curr Opin Mol Ther. 2006 Jun;8(3):240-8 [16774044.001]
  • [Cites] Postepy Hig Med Dosw (Online). 2006;60:483-9 [17013367.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7126-31 [17145837.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):897-905 [17096330.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Jan;22(1):86-91 [17201887.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):309-17 [17210712.001]
  • [Cites] Proteomics. 2007 Feb;7(4):565-77 [17309102.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):9-22 [17613433.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):573-6 [12888832.001]
  • [Cites] Leukemia. 2000 May;14(5):826-9 [10803513.001]
  • [Cites] Mol Cells. 2000 Jun 30;10(3):331-7 [10901172.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):800-10 [10952786.001]
  • [Cites] Brain Res Mol Brain Res. 2000 Nov 10;83(1-2):1-8 [11072090.001]
  • [Cites] J Control Release. 2002 Apr 23;80(1-3):259-71 [11943403.001]
  • [Cites] Cancer Lett. 2002 Sep 26;183(2):155-62 [12065090.001]
  • [Cites] Med Sci Monit. 2002 Jul;8(7):BR248-53 [12118186.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5443-50 [12359751.001]
  • [Cites] Genes Cells. 2003 Jan;8(1):65-79 [12558800.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):613-23 [12592378.001]
  • [Cites] Cancer Lett. 2003 Mar 10;191(2):165-70 [12618329.001]
  • [Cites] Mol Cell Biochem. 2003 Feb;244(1-2):177-85 [12701828.001]
  • [Cites] Eur J Biochem. 2003 May;270(9):1887-99 [12709047.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):723-8 [12866032.001]
  • [Cites] Br J Cancer. 2003 Sep 1;89(5):907-14 [12942125.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1214-6 [14571701.001]
  • [Cites] Biochem Pharmacol. 2003 Nov 15;66(10):1945-52 [14599552.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 9;313(2):443-6 [14684182.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52504-10 [14570901.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):826-33 [14770441.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1815-22 [15143074.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36192-200 [15192091.001]
  • [Cites] Clin Sci (Lond). 2004 Oct;107(4):371-9 [15157183.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):502-8 [15382078.001]
  • [Cites] Anticancer Drugs. 2004 Oct;15(9):825-33 [15457122.001]
  • [Cites] J Nutr. 2004 Oct;134(10 Suppl):2837S-2841S; discussion 2853S [15465796.001]
  • [Cites] Br J Cancer. 1974 Jul;30(1):50-9 [4528778.001]
  • [Cites] Cytogenet Cell Genet. 1979;23(3):171-81 [219990.001]
  • [Cites] Br J Cancer. 1979 Jun;39(6):613-20 [444403.001]
  • [Cites] Eur J Biochem. 1979 Jun;97(1):29-35 [477671.001]
  • [Cites] J Biol Chem. 1981 Nov 25;256(22):11826-31 [6170638.001]
  • [Cites] J Biol Chem. 1982 Mar 10;257(5):2246-53 [7061421.001]
  • (PMID = 18473854.001).
  • [ISSN] 1873-4286
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109578-02; United States / NCI NIH HHS / CA / R01CA109578; United States / NCI NIH HHS / CA / CA109578-03; United States / NCI NIH HHS / CA / R01 CA109578; United States / NCI NIH HHS / CA / CA109578-01; United States / NCI NIH HHS / CA / CA109578-02; United States / NCI NIH HHS / CA / R01 CA109578-01; United States / NCI NIH HHS / CA / R01 CA109578-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 30IQX730WE / Polyethylene Glycols; 94ZLA3W45F / Arginine; EC 3.- / Hydrolases; EC 3.5.3.6 / ADI PEG20; EC 6.3.4.5 / Argininosuccinate Synthase
  • [Number-of-references] 75
  • [Other-IDs] NLM/ NIHMS287629; NLM/ PMC3096551
  •  go-up   go-down


88. Zanelli M, Cortecchia S, Righi E, Caprara L, De Lillo M, Costa F, Galanti G, Bondi A: Epithelioid angiomyolipoma of the kidney: case report. Pathologica; 2008 Jun;100(3):202-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid angiomyolipoma of the kidney: case report.
  • Renal angiomyolipoma is a benign tumour histologically characterized by a mixture of adipose tissue, smooth muscle cells and thick walled blood vessels.
  • Long-believed to be a benign hamartoma, angiomyolipoma is now considered to arise from perivascular epithelioid cells.
  • Epithelioid angiomyolipoma is a rare type of angiomyolipoma, composed partially or completely of epithelioid cells, with a potentially aggressive behaviour.
  • Histologically it can mimic renal cell carcinoma.
  • Positivity for HMB45, Melan A, CD68 and CD117 are useful for diagnosis.
  • Herein, we report the clinicopathologic and immunohistochemical features of a renal tumour composed of large epithelioid mononucleated or multinucleated cells with abundant acidophilic cytoplasm and prominent nucleoli.
  • Despite the morphologic resemblance of this tumour to renal cell carcinoma, its phenotype (HMB45, Melan A and CD68 positivity and keratin negativity) parallels the phenotypic profile of angiomyolipoma.
  • [MeSH-major] Angiomyolipoma / pathology. Kidney Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18841830.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


89. Cánovas D, Martínez JM, Viguera M, Ribera G: [Association of renal carcinoma with neuromyotonia and involvement of inferior motor neuron]. Neurologia; 2007 Jul-Aug;22(6):399-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association of renal carcinoma with neuromyotonia and involvement of inferior motor neuron].
  • [Transliterated title] Asociación de carcinoma renal con neuromiotonía y afectación de neurona motora inferior.
  • It has been considered a paraneoplastic syndrome in patients with neoplasms of the immune system, mainly lymphomas.
  • We report a rare case, given the presence of two uncommon paraneoplastic manifestations such as neuromyotonia and reversible paraneoplastic lower motor neuronopathy secondary to clear cell renal carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / complications. Isaacs Syndrome / etiology. Kidney Neoplasms / complications. Motor Neuron Disease / etiology. Paraneoplastic Syndromes / etiology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17610170.001).
  • [ISSN] 0213-4853
  • [Journal-full-title] Neurología (Barcelona, Spain)
  • [ISO-abbreviation] Neurologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


90. Kölbel T, Rostock T, Larena-Avellaneda A, Treede H, Franzen O, Debus ES: An externalized transseptal guidewire technique to facilitate guidewire stabilization and stent-graft passage in the aortic arch. J Endovasc Ther; 2010 Dec;17(6):744-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TECHNIQUE: The technique of a transseptal through-and-through guidewire is demonstrated in a patient with a ruptured thoracic aneurysm with severe tortuosity of the aorta and a right-sided, severely angulated aortic arch.
  • The transseptal through-and-through guidewire stabilization technique allowed successful passage and deployment of a thoracic stent-graft after debranching of the right common carotid and subclavian arteries.
  • CONCLUSION: An externalized transseptal guidewire can facilitate endograft passage in tortuous aortic anatomies and optimize control in most severely angulated aortic arches.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Endovasc Ther. 2010 Dec;17(6):750 [21142484.001]
  • (PMID = 21142483.001).
  • [ISSN] 1545-1550
  • [Journal-full-title] Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists
  • [ISO-abbreviation] J. Endovasc. Ther.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Maeda K, Yasaka M, Wakugawa Y, Ogata T, Okada Y: [A case of brain infarction and thoracic aortic dissection without chest nor back pain diagnosed by carotid duplex ultrasonography]. Rinsho Shinkeigaku; 2009 Feb-Mar;49(2-3):104-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of brain infarction and thoracic aortic dissection without chest nor back pain diagnosed by carotid duplex ultrasonography].
  • Brain magnetic resonance imaging (MRI) showed multiple acute brain infarction of the right middle cerebral artery territory.
  • Carotid duplex ultrasonography demonstrated a subintimal dissection with a false channel of the right common carotid artery (CCA) and the right internal carotid artery (ICA).
  • Cervical CT scan showed a dissection with a false channel of the right CCA.
  • Thus our patient showed thoracic aortic dissection with extension of the dissection toward the right internal carotid artery.
  • So we emphasize the necessity of carotid duplex ultrasonography examination before intravenous administration of rt-PA in the treatment of the cerebral infarction, regardless of having chest pain, back pain, neck pain or not.
  • [MeSH-major] Aneurysm, Dissecting / diagnosis. Aortic Aneurysm, Thoracic / diagnosis. Carotid Arteries / ultrasonography. Cerebral Infarction / diagnosis. Ultrasonography, Doppler, Duplex

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19348175.001).
  • [ISSN] 0009-918X
  • [Journal-full-title] Rinshō shinkeigaku = Clinical neurology
  • [ISO-abbreviation] Rinsho Shinkeigaku
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


92. Haas NB, Uzzo RG: Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer. Curr Treat Options Oncol; 2007 Jun;8(3):211-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer.
  • Renal cell carcinoma (RCC) is a heterogeneous disease as reflected in its presentation and clinical course, pathological subtypes, nuclear grades and molecular biology.
  • Emerging data indicate that renal tumors express a variety of molecular tumor markers and unique patterns of gene expression.
  • Clinically the disease behaves quite heterogeneously, with courses ranging from indolent to highly aggressive.
  • Surgical monotherapy or as part of a multimodal approach remains the standard of care for most cases of RCC.
  • Radical or partial nephrectomy is associated with a 5-year cancer specific survival (CSS) of 85-97% for pT1 tumors.
  • Unfortunately, 20% of patients have either locally advanced or node positive (N+) RCC while another 22% have metastatic RCC (mRCC) at presentation.
  • Unlike the outcomes in early localized disease, survival rates for N+ patients are poor and patients with mRCC are rarely cured despite aggressive multimodal therapy.
  • Recent advances in our understanding of the molecular origins and pathways of RCC have led to the development of more effective targeted therapies.
  • Here we review the molecular pathways that define the pertinent therapeutic targets in RCC and the clinical data for these new and promising agents.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Aug 10;23 (23 ):5294-304 [15998902.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1363-9 [16446323.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6680-6 [11426655.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):2900-2 [15860848.001]
  • [Cites] N Engl J Med. 2001 Dec 6;345(23 ):1655-9 [11759643.001]
  • [Cites] Urol Clin North Am. 2003 Aug;30(3):423-36 [12953746.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2477-90 [16339096.001]
  • [Cites] J Surg Oncol. 2005 Sep 1;91(3):173-80 [16118771.001]
  • [Cites] Nature. 1994 Jun 30;369(6483):756-8 [8008069.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Urol. 2006 Feb;175(2):459-62 [16406971.001]
  • [Cites] Nat Genet. 1997 May;16(1):68-73 [9140397.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5549-54 [16740688.001]
  • [Cites] Semin Oncol. 1995 Feb;22(1):3-8 [7855617.001]
  • [Cites] J Urol. 2005 Jun;173(6):1889-92 [15879769.001]
  • [Cites] Curr Urol Rep. 2007 Jan;8(1):19-30 [17239313.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Am J Pathol. 1994 Aug;145(2):356-64 [7519827.001]
  • [Cites] Ann Intern Med. 2006 Nov 7;145(9):660-4 [17088579.001]
  • [Cites] J Biol Chem. 1993 Oct 25;268(30):22825-9 [8226793.001]
  • [Cites] Urol Clin North Am. 1993 May;20(2):303-21 [8493752.001]
  • [Cites] Ann Intern Med. 1984 Dec;101(6):798-9 [6497196.001]
  • [Cites] Lancet. 2001 Sep 22;358(9286):966-70 [11583750.001]
  • [Cites] J Urol. 2006 Feb;175(2):425-31 [16406965.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2516-24 [16757724.001]
  • [Cites] Blood. 2005 Feb 1;105(3):986-93 [15459012.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):e48 [17008686.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):491-500 [15992698.001]
  • [Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]
  • [Cites] Mol Carcinog. 2001 Jul;31(3):161-70 [11479925.001]
  • [Cites] Annu Rev Genet. 1986;20:231-51 [2880556.001]
  • [Cites] Hum Mol Genet. 1994 Dec;3(12):2169-73 [7881415.001]
  • [Cites] J Urol. 2005 Jun;173(6):1903-7 [15879772.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10 (8):2584-6 [15102658.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2323-33 [16240452.001]
  • [Cites] Ann Intern Med. 2005 Aug 16;143(4):313-4 [16103482.001]
  • [Cites] Cancer. 2006 Nov 15;107(10):2375-83 [17048248.001]
  • [Cites] JAMA. 1995 Feb 15;273(7):564-70 [7837390.001]
  • [Cites] N Engl J Med. 2003 Jul 31;349(5):427-34 [12890841.001]
  • [Cites] Eur J Cancer. 2006 Aug;42(12 ):1875-80 [16806903.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):759-65 [17103075.001]
  • [Cites] Mol Cancer Ther. 2006 Apr;5(4):995-1006 [16648571.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Blood. 2003 May 1;101(9):3597-605 [12531805.001]
  • [Cites] Invest New Drugs. 2005 Aug;23(4):357-61 [16012795.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):1047-52 [11792863.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):517-26 [10433944.001]
  • [Cites] Lancet. 2004 Feb 21;363(9409):594-9 [14987883.001]
  • [Cites] Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425 [15674877.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):327-37 [12538485.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1477-9 [17116839.001]
  • (PMID = 17712534.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Number-of-references] 68
  •  go-up   go-down


93. Wethkamp N, Ramp U, Geddert H, Schulz WA, Florl AR, Suschek CV, Hassan M, Gabbert HE, Mahotka C: Expression of death-associated protein kinase during tumour progression of human renal cell carcinomas: hypermethylation-independent mechanisms of inactivation. Eur J Cancer; 2006 Jan;42(2):264-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of death-associated protein kinase during tumour progression of human renal cell carcinomas: hypermethylation-independent mechanisms of inactivation.
  • Death-associated protein kinase (DAPK) is a pro-apoptotic Ca(2+)/calmodulin-dependent serine/threonine kinase that is widely expressed in tissues but kept silent in growing cells.
  • Downregulation of DAPK transcription by CpG methylation has been demonstrated in a variety of tumours, providing a selective growth advantage during tumour progression.
  • As the in vivo expression of DAPK in human renal cell carcinomas (RCCs) has not previously been analysed, 72 RCCs were investigated using semi-quantitative real-time reverse transcription polymerase chain reaction (RT-PCR).
  • We found that almost 92% (66/72) of all primary RCCs express DAPK mRNA and results obtained from methylation-specific PCR analyses suggest that aberrant CpG methylation of the DAPK promoter is absent even in DAPK non-expressing tumours.
  • Comparison of early/intermediate with advanced tumour stages of clear cell RCCs showed that no significant changes in the expression levels of DAPK were evident.
  • Chromophilic/papillary RCCs display no significantly different expression patterns of DAPK compared with stage-adjusted clear cell RCCs.
  • Furthermore, on analysing the DAPK enzyme activity in RCC cell lines with DAPK mRNA and protein expression, only 1 out of 11 cell lines showed basal DAPK activity in kinase activity assays, suggesting that DAPK, although expressed in RCC, remains largely inactive.
  • Our study demonstrates the in vivo expression of DAPK in RCCs and reveals that, in contrast to other tumour types, RCCs may not downregulate DAPK mRNA expression during tumour progression.
  • Despite persistent DAPK transcription and translation, however, the markedly reduced DAPK enzyme activity in our RCC cell lines suggested a post-translational inactivation of DAPK in RCCs.
  • [MeSH-major] Calcium-Calmodulin-Dependent Protein Kinases / metabolism. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / metabolism
  • [MeSH-minor] Apoptosis Regulatory Proteins. Cell Line, Tumor. DNA Methylation. Death-Associated Protein Kinases. Disease Progression. Humans. RNA, Messenger / metabolism. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16386893.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases
  •  go-up   go-down


94. Liu H, Brannon AR, Reddy AR, Alexe G, Seiler MW, Arreola A, Oza JH, Yao M, Juan D, Liou LS, Ganesan S, Levine AJ, Rathmell WK, Bhanot GV: Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. BMC Syst Biol; 2010;4:51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma.
  • RESULTS: We describe a simple method to identify direct mRNA targets of microRNA dysregulated in cancers from expression level measurements in patient matched tumor/normal samples.
  • The word "direct" is used here in a strict sense to: a) represent mRNA which have an exact seed sequence match to the microRNA in their 3'UTR, b) the seed sequence match is strictly conserved across mouse, human, rat and dog genomes, c) the mRNA and microRNA expression levels can distinguish tumor from normal with high significance and d) the microRNA/mRNA expression levels are strongly and significantly anti-correlated in tumor and/or normal samples.
  • We apply and validate the method using clear cell Renal Cell Carcinoma (ccRCC) and matched normal kidney samples, limiting our analysis to mRNA targets which undergo degradation of the mRNA transcript because of a perfect seed sequence match.
  • Dysregulated microRNA and mRNA are first identified by comparing their expression levels in tumor vs normal samples.
  • These are further pruned by requiring a strong anti-correlation signature in tumor and/or normal samples.
  • The method revealed many new regulations in ccRCC.
  • For instance, loss of miR-149, miR-200c and mir-141 causes gain of function of oncogenes (KCNMA1, LOX), VEGFA and SEMA6A respectively and increased levels of miR-142-3p, miR-185, mir-34a, miR-224, miR-21 cause loss of function of tumor suppressors LRRC2, PTPN13, SFRP1, ERBB4, and (SLC12A1, TCF21) respectively.
  • Several identified microRNA/mRNA pairs were validated on an independent set of matched ccRCC/normal samples.
  • CONCLUSIONS: We describe a simple and reliable method to identify direct gene targets of microRNA in any cancer.
  • The constraints we impose (strong dysregulation signature for microRNA and mRNA levels between tumor/normal samples, evolutionary conservation of seed sequence and strong anti-correlation of expression levels) remove spurious matches and identify a subset of robust, tissue specific, functional mRNA targets of dysregulated microRNA.
  • [MeSH-major] Carcinoma, Renal Cell / metabolism. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Kidney Neoplasms / metabolism. RNA, Messenger / metabolism